<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006643</article-id><article-id pub-id-type="pmc">PMC11859495</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020276</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3457-2528</contrib-id><name><surname>Kozak</surname><given-names>Andreja</given-names></name><xref rid="af1-pharmaceutics-17-00276" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lavrih</surname><given-names>Ernestina</given-names></name><xref rid="af1-pharmaceutics-17-00276" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00276" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1513-9825</contrib-id><name><surname>Mikhaylov</surname><given-names>Georgy</given-names></name><xref rid="af1-pharmaceutics-17-00276" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9007-5764</contrib-id><name><surname>Turk</surname><given-names>Boris</given-names></name><xref rid="af1-pharmaceutics-17-00276" ref-type="aff">1</xref><xref rid="af3-pharmaceutics-17-00276" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Vasiljeva</surname><given-names>Olga</given-names></name><xref rid="af1-pharmaceutics-17-00276" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00276" ref-type="corresp">*</xref><xref rid="fn1-pharmaceutics-17-00276" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Duzgunes</surname><given-names>Nejat</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00276"><label>1</label>Department of Biochemistry and Molecular and Structural Biology, Jo&#x0017e;ef Stefan Institute, 1000 Ljubljana, Slovenia; <email>andreja.kozak@ijs.si</email> (A.K.); <email>ernestina.lavrih@ijs.si</email> (E.L.); <email>georgy.mikhaylov@ijs.si</email> (G.M.); <email>boris.turk@ijs.si</email> (B.T.)</aff><aff id="af2-pharmaceutics-17-00276"><label>2</label>Jo&#x0017e;ef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia</aff><aff id="af3-pharmaceutics-17-00276"><label>3</label>Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia</aff><author-notes><corresp id="c1-pharmaceutics-17-00276"><label>*</label>Correspondence: <email>olga.vasiljeva@ijs.si</email></corresp><fn id="fn1-pharmaceutics-17-00276"><label>&#x02020;</label><p>Current address: CytomX Therapeutics, Inc., South San Francisco, CA 94080, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>276</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Liposome-based targeted drug delivery systems represent a significant advancement in pharmaceutical science, offering distinct advantages that enhance the efficacy and safety of various therapies. These versatile carriers can encapsulate both hydrophilic and hydrophobic drugs, making them particularly valuable in clinical settings. This review explores the critical role of liposomal formulations in improving drug pharmacokinetics and minimizing side effects, especially in oncology, where targeted delivery to tumor cells is essential. Outlining the properties of different types of liposomes, we focus on the effects of these properties on the liposomes&#x02019; targeting and drug release capabilities through innovative surface modifications and describe the most common methods of liposome preparation and characterization. Furthermore, this review provides an in-depth analysis of the properties and composition of liposomal-based nanocarriers, with a unique focus on ongoing clinical trials and recently approved therapies. It offers a comprehensive overview of the latest advancements in pre-clinical research and highlights the critical progress in clinical development, offering insights into the clinical impact and regulatory approvals. Ultimately, this review underscores the transformative potential of liposomal nanocarriers in modern therapeutics, suggesting avenues for future innovations and clinical breakthroughs.</p></abstract><kwd-group><kwd>liposomes</kwd><kwd>drug delivery</kwd><kwd>cancer treatment</kwd><kwd>controlled drug release</kwd><kwd>clinical trials</kwd><kwd>clinical applications</kwd></kwd-group><funding-group><award-group><funding-source>Slovenian Research and Innovation Agency</funding-source><award-id>P1-0140</award-id></award-group><funding-statement>This research was funded by the Slovenian Research and Innovation Agency, grant number P1-0140.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00276"><title>1. Introduction</title><p>Efficient drug delivery to tumors is one of the key challenges in cancer treatment that often limits therapeutic success and patient outcomes. Drug delivery systems have the potential to improve the therapeutic index by increasing drug concentration and residence time, and by minimizing side effects [<xref rid="B1-pharmaceutics-17-00276" ref-type="bibr">1</xref>]. These systems have to overcome multiple challenges in the tumor microenvironment (TME), such as dense stroma or increased interstitial fluid pressure keeping the therapeutic agents from reaching their target. Low bioavailability due to fast elimination from circulation or biotransformation is a frequently encountered obstacle that can be significantly improved with an efficient delivery system [<xref rid="B2-pharmaceutics-17-00276" ref-type="bibr">2</xref>].</p><p>Drug delivery nanocarriers include a plethora of different types of nanoparticles: lipid-based vesicles, such as micelles or liposomes; metallic nanoparticles, including nanoshells and quantum dots; many different types of polymeric systems, such as dendrimers; viral nanocarriers; carbon nanotubes; and others [<xref rid="B3-pharmaceutics-17-00276" ref-type="bibr">3</xref>]. However, not many of these systems have been approved by the FDA, while more are in clinical trials [<xref rid="B4-pharmaceutics-17-00276" ref-type="bibr">4</xref>]. Among the most promising and most explored systems are liposomes&#x02014;spherical lipid vesicles composed of one or more lipid bilayers [<xref rid="B5-pharmaceutics-17-00276" ref-type="bibr">5</xref>]. Liposomes were first described by Alec Bangham in 1961 and have since then become the most widely used nanocarrier in targeted drug delivery [<xref rid="B6-pharmaceutics-17-00276" ref-type="bibr">6</xref>]. Their success is due to their convenient characteristics: high biocompatibility, biodegradability, easy functionalization, low toxicity, and immunogenicity. In addition, they offer the option to encapsulate hydrophilic drugs into their aqueous interior, while lipophilic compounds can be incorporated into the lipid bilayer [<xref rid="B5-pharmaceutics-17-00276" ref-type="bibr">5</xref>].</p><p>Liposomal drug delivery systems have been successfully translated into clinical settings. The first FDA-approved drug was Doxil<sup>&#x000ae;</sup>, liposomal doxorubicin used to treat ovarian cancer, introduced in 1995 [<xref rid="B7-pharmaceutics-17-00276" ref-type="bibr">7</xref>]. In the following years, more liposomal cancer treatments were developed and, to a lesser degree, some liposomal formulations for other diseases such as fungal infections. Liposomes have also become an important carrier system for vaccine development, such as vaccines for hepatitis and influenza [<xref rid="B8-pharmaceutics-17-00276" ref-type="bibr">8</xref>]. More recently, lipid nanoparticles, a delivery system based on liposomes, were used in the development of mRNA vaccines for COVID-19 [<xref rid="B9-pharmaceutics-17-00276" ref-type="bibr">9</xref>].</p><p>This review will focus on the clinical applications of liposomal drug delivery systems in cancer treatment, highlighting their advantages and limitations in real-world settings, as well as exploring future clinical avenues for their optimization and broader therapeutic impact.</p></sec><sec id="sec2-pharmaceutics-17-00276"><title>2. Liposomal Drug Delivery Systems</title><p>Liposomes are nanosized lipid spheres, composed of lipid bilayers, as opposed to the related nanostructures of micelles, which contain a lipid monolayer. Based on their size and number of bilayers, liposomes can be classified into distinct categories: multilamellar vesicles (MLVs) contain several bilayers and are usually larger than 500 nm in diameter; unilamellar vesicles are composed of one lipid bilayer and can be further categorized as large unilamellar vesicles (LUVs), which are bigger than 100 nm in diameter, and small unilamellar vesicles (SUVs), with diameters of less than 100 nm. Another class of liposomes is multivesicular vesicles (MVVs), which contain many unilamellar vesicles within larger liposomes. MVVs range in size from 1 to 100 &#x000b5;m in diameter. The size of the vesicles is an important factor in determining the system&#x02019;s circulation half-life and uptake, as well as its encapsulation efficiency. The liposomes employed in drug delivery systems are most often unilamellar and range in size from 50 to 150 nm [<xref rid="B10-pharmaceutics-17-00276" ref-type="bibr">10</xref>].</p><p>The lipid bilayer significantly impacts many characteristics of the liposomes, which are crucial for their efficacy as drug delivery vehicles. Liposomal membranes are comprised mainly of phospholipids, which can be natural or synthetic; in general, liposomes comprised of natural phospholipids are less stable than those of synthetic. Lipid composition highly affects the characteristics of liposomes, such as particle size, rigidity, fluidity, stability, and electrical charge [<xref rid="B11-pharmaceutics-17-00276" ref-type="bibr">11</xref>]. A phospholipid molecule is bipolar, composed of hydrophobic fatty acyl chains, a glycerol or sphingosine backbone, and a hydrophilic headgroup. Another crucial component of the bilayer is steroids&#x02014;the major steroid used in liposome preparation is cholesterol, which improves liposomal rigidity and stability [<xref rid="B12-pharmaceutics-17-00276" ref-type="bibr">12</xref>].</p><sec id="sec2dot1-pharmaceutics-17-00276"><title>2.1. Types of Liposomes</title><p>Conventional liposomes, or liposomes of the first generation, were comprised only of natural or synthetic phospholipids [<xref rid="B13-pharmaceutics-17-00276" ref-type="bibr">13</xref>]. Very soon, cholesterol was added to improve liposome membrane rigidity. These liposomes showed excellent tumor penetration and anti-tumor activity; however, their blood circulation time was low due to elimination by the mononuclear phagocyte system, and they have shown limited stability in vitro [<xref rid="B14-pharmaceutics-17-00276" ref-type="bibr">14</xref>].</p><p>In comparison, charged liposomes are more stable during storage as they repel each other and are thus less prone to aggregation. Cationic liposomes are used in gene therapy due to their ability to encapsulate nucleic acids [<xref rid="B15-pharmaceutics-17-00276" ref-type="bibr">15</xref>]. They are also considered as potential tools to deliver drugs to the brain, since they can cross the blood&#x02013;brain barrier [<xref rid="B16-pharmaceutics-17-00276" ref-type="bibr">16</xref>]. Anionic liposomes are less stable in the bloodstream compared to neutral and cationic liposomes; however, they can be used for transdermal drug delivery as they have been shown to improve penetration properties through the skin [<xref rid="B17-pharmaceutics-17-00276" ref-type="bibr">17</xref>].</p><p>Second-generation liposomes were developed to tackle the problem of rapid clearance from circulation. Polyethylene glycol was added to the surface of the liposomes to increase their steric protection and to inhibit their recognition by the mononuclear phagocyte system. The PEGylated liposomes were named &#x02018;stealth&#x02019; liposomes and showed improved circulation time and better target accumulation compared to conventional liposomes [<xref rid="B18-pharmaceutics-17-00276" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00276" ref-type="bibr">19</xref>]. Stealth liposomes accumulate in the target tissue by passive targeting. This approach takes advantage of the enhanced permeability and retention (EPR) effect of the vasculature, brought on by abnormal leaky blood vessels and the lack of functional lymphatics in the tumor tissue [<xref rid="B20-pharmaceutics-17-00276" ref-type="bibr">20</xref>]. This effect is aided by the increased blood circulation time of the stealth liposomes; however, the EPR effect alone cannot completely attenuate the side effects of cytotoxic drugs. Additionally, it is limited to solid tumors. These limitations led to the development of active targeting.</p><sec id="sec2dot1dot1-pharmaceutics-17-00276"><title>2.1.1. Actively Targeted Liposomes</title><p>The active targeting approach enhances the targeting efficiency of liposomal carriers, improving therapeutic outcomes and minimizing the potential toxicity. One of the first active targeting approaches explored involves the use of liposomes integrated with magnetic nanoparticles. By applying an external magnetic field, these magnetized liposomes can be precisely directed to tumor sites, enhancing the targeting efficiency and improving therapeutic outcomes while reducing the impact on healthy tissues [<xref rid="B21-pharmaceutics-17-00276" ref-type="bibr">21</xref>]. An example of this approach is the use of ferri-liposomes, which encapsulate ferrimagnetic iron oxide nanoparticles [<xref rid="B22-pharmaceutics-17-00276" ref-type="bibr">22</xref>]. These liposomes, when exposed to a magnetic field, can target tumors effectively, slow tumor growth in mouse models, and offer simultaneous drug delivery and MRI-based detection.</p><p>A classic active targeting strategy involves attaching targeting ligands to the liposomal surface, thus enhancing the delivery of the liposomal systems. Various molecules have been used as targeting ligands: antibodies, nucleic acids, peptides, proteins, and small molecules [<xref rid="B23-pharmaceutics-17-00276" ref-type="bibr">23</xref>]. Several aspects are considered when selecting a targeting ligand: (i) the overexpression or selective expression of the target in the targeted tissue, (ii) the uptake of the targeted formulation by the target cells, and (iii) the degree of covering of the target molecule [<xref rid="B24-pharmaceutics-17-00276" ref-type="bibr">24</xref>]. The most commonly used targeting agents are antibodies; liposomes functionalized with antibodies are termed immuno-liposomes [<xref rid="B25-pharmaceutics-17-00276" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00276" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00276" ref-type="bibr">27</xref>]. Monoclonal antibodies against receptors, such as HER2 [<xref rid="B28-pharmaceutics-17-00276" ref-type="bibr">28</xref>], EGFR [<xref rid="B29-pharmaceutics-17-00276" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00276" ref-type="bibr">30</xref>], and transferrin receptor [<xref rid="B31-pharmaceutics-17-00276" ref-type="bibr">31</xref>], among others, have been successfully used to prepare immuno-liposomes. Some of these formulations have the added benefit of blocking the targeted receptor, resulting in increased anti-cancer activity [<xref rid="B28-pharmaceutics-17-00276" ref-type="bibr">28</xref>,<xref rid="B32-pharmaceutics-17-00276" ref-type="bibr">32</xref>]. Efforts in developing cancer-targeting liposomes have focused not only on cancer cells, but also on the tumor microenvironment; the targets include various overexpressed proteases, such as cathepsins [<xref rid="B33-pharmaceutics-17-00276" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00276" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00276" ref-type="bibr">35</xref>] or MMPs, vascular cell adhesion molecules [<xref rid="B36-pharmaceutics-17-00276" ref-type="bibr">36</xref>], and integrins [<xref rid="B37-pharmaceutics-17-00276" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00276" ref-type="bibr">38</xref>].</p><p>One of the very first applications of a liposomal nanocarrier attached to a small molecule targeting a tumor-associated protease, cathepsin B (CtsB), was described by Mikhaylov et al. in 2014 [<xref rid="B33-pharmaceutics-17-00276" ref-type="bibr">33</xref>]. A selective CtsB inhibitor conjugated to a PEG-functionalized lipid was incorporated into the envelope of a liposomal nanocarrier. The resulted targeted drug delivery system, LNC-NS-629, was demonstrated to be efficient in targeting a clinical MRI contrast agent to the tumor in a mouse breast cancer model (<xref rid="pharmaceutics-17-00276-f001" ref-type="fig">Figure 1</xref>).</p><p>The efforts to target cysteine cathepsins were further pursued by functionalizing liposomes with the endogenous cysteine cathepsins inhibitor stefin A [<xref rid="B34-pharmaceutics-17-00276" ref-type="bibr">34</xref>]. The novel delivery system was shown to selectively target cathepsins in vitro and in vivo. In an additional study, the aspartic protease cathepsin D was targeted using pepstatin A&#x02014;its natural peptide inhibitor [<xref rid="B35-pharmaceutics-17-00276" ref-type="bibr">35</xref>]. The pepstatin A-functionalized liposomes were efficient in targeting cathepsin D in cancer cell lines, showing potential for their use in vivo.</p><p>Although the concept of active targeting is very promising and numerous studies have focused on developing novel actively targeted systems, there are some limitations, among them the higher development costs for targeted liposomes; this might be the reason progress to the clinic has been slow [<xref rid="B39-pharmaceutics-17-00276" ref-type="bibr">39</xref>].</p></sec><sec id="sec2dot1dot2-pharmaceutics-17-00276"><title>2.1.2. Triggered Liposomes</title><p>The stability of liposomes in circulation and the retention of their contents are key characteristics for a successful delivery system. Efforts have therefore been employed in the development of triggered liposomes, which would protect the encapsulated drug during trafficking and release their contents upon reaching the target tissue. There are two major types of triggers used to produce this effect: remote triggers, such as heat, ultrasound, and light, and local triggers intrinsic to the targeted tissue, such as enzymes and pH distortions [<xref rid="B40-pharmaceutics-17-00276" ref-type="bibr">40</xref>]. The exploitation of these triggers has resulted in the development of several advanced technologies, such as thermosensitive liposomes [<xref rid="B41-pharmaceutics-17-00276" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00276" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00276" ref-type="bibr">43</xref>], light-sensitive liposomes [<xref rid="B44-pharmaceutics-17-00276" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00276" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-00276" ref-type="bibr">46</xref>], echogenic liposomes triggered by ultrasound [<xref rid="B47-pharmaceutics-17-00276" ref-type="bibr">47</xref>], enzyme-responsive liposomes [<xref rid="B48-pharmaceutics-17-00276" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-17-00276" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-00276" ref-type="bibr">50</xref>], and pH-sensitive liposomes [<xref rid="B51-pharmaceutics-17-00276" ref-type="bibr">51</xref>].</p><p>The first generation of triggered liposomes employed thermosensitivity to release the encapsulated drug in response to temperature fluctuations [<xref rid="B42-pharmaceutics-17-00276" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-00276" ref-type="bibr">43</xref>] that could be achieved by the application of an external heating source, such as a water bath, laser, or electromagnet [<xref rid="B52-pharmaceutics-17-00276" ref-type="bibr">52</xref>]. Thermosensitive liposomes were initially developed by adjusting the lipid bilayer components to achieve a transition temperature (Tm) around 41 &#x000b0;C, at which point the bilayer shifts from a solid gel phase to a liquid crystalline phase, triggering the release of the encapsulated compounds [<xref rid="B53-pharmaceutics-17-00276" ref-type="bibr">53</xref>]. Newer developments led to the inclusion of thermosensitive polymers, offering more tunability [<xref rid="B54-pharmaceutics-17-00276" ref-type="bibr">54</xref>]. Several thermosensitive liposome formulations have been evaluated in clinical trials. One of the leading clinical trials of ThermoDox<sup>&#x000ae;</sup>, a lyso-thermosensitive liposomal doxorubicin (LTLD), has progressed to the phase III stage, with two trials completed [<xref rid="B55-pharmaceutics-17-00276" ref-type="bibr">55</xref>]. The initial phase III clinical trial known as the HEAT trial evaluated the combination of ThermoDox<sup>&#x000ae;</sup> with radiofrequency ablation (RFA) compared to RFA alone for the treatment of inoperable hepatocellular carcinoma (HCC). Although conducted on 701 patients across 55 centers globally, the trial did not meet its primary endpoint of progression-free survival (PFS). The subsequent phase III OPTIMA trial, including 556 patients who were treated with ThermoDox<sup>&#x000ae;</sup> and underwent RFA for at least 45 min, did not show statistically significant improvement in the primary endpoint. While certain patient subgroups appeared to show clinical benefit, the company decided not to pursue these retrospective findings due to the significant regulatory challenges that could impact further development. Despite these setbacks, both trials provided valuable insights into the challenges of combining thermally activated drug delivery systems with RFA, highlighting the need for continued research to optimize treatment protocols, heating modalities, and other factors for better therapeutic outcomes [<xref rid="B56-pharmaceutics-17-00276" ref-type="bibr">56</xref>].</p><p>Light-sensitive or photoactivatable liposomes incorporate components that respond to light in their structure. These molecules can be photosensitizers, which generate reactive oxygen species, or they can undergo a conformational change, cleavage, polymerization, or generate heat after absorbing light [<xref rid="B57-pharmaceutics-17-00276" ref-type="bibr">57</xref>]. The changes in the molecules following exposure to light leads to the destabilization of the liposome membrane, resulting in the release of the drug cargo. The first photoresponsive liposome preparation was described in 1981 by Kano et al. Light as an activation stimulus offers high spatial and temporal control for drug release, while being non-invasive. However, some challenges still hinder the translation of this technology to clinics&#x02014;low tissue penetration and concerns regarding UV phototoxicity [<xref rid="B58-pharmaceutics-17-00276" ref-type="bibr">58</xref>]. An additional drawback, common to all remotely triggered liposomal release systems in cancer, is that they can only target primary tumors, while patients mostly die from metastatic disease [<xref rid="B39-pharmaceutics-17-00276" ref-type="bibr">39</xref>].</p><p>pH-sensitive liposomes take advantage of the lowered extracellular pH in tumors, thus providing a local stimulus for drug release [<xref rid="B59-pharmaceutics-17-00276" ref-type="bibr">59</xref>]. These liposomes are often composed of compounds that are protonated at an acidic pH and thus destabilize the liposomal membrane, or of compounds that undergo conformational changes at an acidic pH [<xref rid="B60-pharmaceutics-17-00276" ref-type="bibr">60</xref>]. Newer strategies include pH-sensitive polymers incorporated into the liposomal membrane [<xref rid="B61-pharmaceutics-17-00276" ref-type="bibr">61</xref>]. Like conventional liposomes, pH-sensitive liposomes also faced the problem of being eliminated from circulation too quickly; therefore, PEG coating was added to prolong their circulation time [<xref rid="B62-pharmaceutics-17-00276" ref-type="bibr">62</xref>]. These liposomes are also internalized more efficiently, which might be beneficial for bypassing drug transporters in MDR2-overexpressing tumor cells, thus evading drug resistance [<xref rid="B63-pharmaceutics-17-00276" ref-type="bibr">63</xref>].</p><p>Another approach using local stimuli is enzyme-responsive liposomes, which take advantage of the enzymes overexpressed in the tumor tissue [<xref rid="B53-pharmaceutics-17-00276" ref-type="bibr">53</xref>]. Research has mostly been focused on liposomes triggered by phospholipases [<xref rid="B49-pharmaceutics-17-00276" ref-type="bibr">49</xref>,<xref rid="B64-pharmaceutics-17-00276" ref-type="bibr">64</xref>] and matrix metalloproteases [<xref rid="B50-pharmaceutics-17-00276" ref-type="bibr">50</xref>,<xref rid="B65-pharmaceutics-17-00276" ref-type="bibr">65</xref>]. To achieve activation by phospholipase, the lipids used need to be degradable by this enzyme, while for activation by MMPs, specialized lipopeptides that are substrates for the MMPs need to be utilized [<xref rid="B66-pharmaceutics-17-00276" ref-type="bibr">66</xref>].</p></sec><sec id="sec2dot1dot3-pharmaceutics-17-00276"><title>2.1.3. Multifunctional Liposomes</title><p>Different features of liposomes can be combined to yield multifunctional liposomes (<xref rid="pharmaceutics-17-00276-f002" ref-type="fig">Figure 2</xref>). Theranostic liposomes include diagnostic and therapeutic functions and allow for the monitoring of real-time delivery, easier determination of therapy responses, and more accurate diagnoses [<xref rid="B67-pharmaceutics-17-00276" ref-type="bibr">67</xref>]. Theranostic liposomes should include an imaging modality, which can be an optical dye for fluorescence imaging [<xref rid="B68-pharmaceutics-17-00276" ref-type="bibr">68</xref>] or a contrast agent for magnetic resonance imaging (MRI) [<xref rid="B69-pharmaceutics-17-00276" ref-type="bibr">69</xref>], computed tomography (CT) [<xref rid="B70-pharmaceutics-17-00276" ref-type="bibr">70</xref>], positron emission tomography (PET) [<xref rid="B71-pharmaceutics-17-00276" ref-type="bibr">71</xref>], single-photon emission computed tomography (SPECT) [<xref rid="B72-pharmaceutics-17-00276" ref-type="bibr">72</xref>], and photoacoustic imaging [<xref rid="B73-pharmaceutics-17-00276" ref-type="bibr">73</xref>], or even a combination of multiple modalities [<xref rid="B74-pharmaceutics-17-00276" ref-type="bibr">74</xref>].</p><p>Theranostic liposomes have been mostly developed for cancer therapy and thus combine the imaging modality with anti-cancer drugs, which can be chemotherapeutics or various sensitizing agents. Often, targeting molecules are also added to the theranostic system. A few examples of this technology include ferri-liposomes loaded with iron oxide for MRI and magnetic targeting as well as doxorubicin [<xref rid="B22-pharmaceutics-17-00276" ref-type="bibr">22</xref>], TME-targeted liposomes loaded with Magnevist for MRI and doxorubicin [<xref rid="B33-pharmaceutics-17-00276" ref-type="bibr">33</xref>], nano-liposomes encapsulating the contrast agent iodixanol and photosensitizers for CT imaging-guided phototherapy of cervical cancer [<xref rid="B75-pharmaceutics-17-00276" ref-type="bibr">75</xref>], iron oxide liposomes loaded with doxorubicin [<xref rid="B76-pharmaceutics-17-00276" ref-type="bibr">76</xref>], gold-containing liposomes with radioisotopes for breast cancer photothermal therapy combined with PET imaging [<xref rid="B77-pharmaceutics-17-00276" ref-type="bibr">77</xref>], transferrin receptor-targeted gold-based liposomes containing the chemotherapeutic docetaxel for brain-targeted drug delivery and imaging [<xref rid="B78-pharmaceutics-17-00276" ref-type="bibr">78</xref>], and folate-targeted liposomes encapsulating paclitaxel and vinorelbine for anti-cancer activity as well as the radioisotope Tc-99m for SPECT/CT imaging [<xref rid="B79-pharmaceutics-17-00276" ref-type="bibr">79</xref>]. These studies demonstrate the versatility of the liposomal platforms and their potential in combining many different modalities, potentially leading to more effective combination therapies.</p><p>Another approach to label liposomes can be achieved by the incorporation of fluorescent lipids. First, they can trigger rapid membrane fusion between cellular plasma membranes and the lipid bilayers of their carrier particles, so-called fusogenic liposomes, and second, after insertion into the cellular membranes, they can enable fluorescence imaging of the traffic processes and fusion with the cell membranes [<xref rid="B80-pharmaceutics-17-00276" ref-type="bibr">80</xref>].</p></sec></sec><sec id="sec2dot2-pharmaceutics-17-00276"><title>2.2. Liposome Preparation and Characterization</title><p>The first developed and still the most common method used to prepare liposomes was thin-film hydration, where all lipids and other hydrophobic components are dissolved in a suitable organic solvent. The solvent is then gently evaporated and the obtained thin film is hydrated with an aqueous buffer solution [<xref rid="B81-pharmaceutics-17-00276" ref-type="bibr">81</xref>] (<xref rid="pharmaceutics-17-00276-f003" ref-type="fig">Figure 3</xref>). Other traditional methods for liposome preparation include reverse-phase evaporation [<xref rid="B82-pharmaceutics-17-00276" ref-type="bibr">82</xref>], ethanol injection [<xref rid="B83-pharmaceutics-17-00276" ref-type="bibr">83</xref>], high-pressure homogenization, the freeze&#x02013;thaw method, detergent removal, and others [<xref rid="B82-pharmaceutics-17-00276" ref-type="bibr">82</xref>]. Most of these methods produce MLVs or LUVs; if smaller unilamellar vesicles need to be prepared, the next step is often sonication or extrusion through a polycarbonate membrane [<xref rid="B84-pharmaceutics-17-00276" ref-type="bibr">84</xref>]. Drug loading is another crucial step in liposome preparation and can be done passively or actively. Passive loading entraps hydrophilic molecules in the aqueous core during lipid bilayer formation, while hydrophobic molecules are dried together with the lipids and thus incorporated in the lipid bilayer. Passive loading has some major drawbacks, such as drug leakage, low encapsulation efficiency, and bilayer destabilization [<xref rid="B84-pharmaceutics-17-00276" ref-type="bibr">84</xref>]. To improve the efficiency of drug loading, active or remote loading has been developed. This approach relies on the creation of an ionic or pH gradient across the liposomal membrane. Uncharged drugs are added to preformed liposomes and can cross the membrane, but once they enter the liposomal core, they become protonated and can no longer pass the bilayer. However, this approach works only for some compounds, ideally for amphipathic weak bases or weak acids [<xref rid="B85-pharmaceutics-17-00276" ref-type="bibr">85</xref>].</p><p>After production and before application, liposomes need to be well evaluated for their physical and chemical properties to ensure their performance. The size and the polydispersity index (PDI) are the most relevant features in liposome characterization. It has been shown that size influences the circulation time of liposomes, with large liposomes being eliminated more quickly [<xref rid="B86-pharmaceutics-17-00276" ref-type="bibr">86</xref>]. For drug delivery, liposomes sized between 50 and 200 nm are considered ideal. The PDI value refers to the heterogeneity of the liposomes&#x02019; sizes in the sample. A lower value indicates a more uniform sample, which is more suitable for drug delivery applications [<xref rid="B87-pharmaceutics-17-00276" ref-type="bibr">87</xref>]. The most common method used to measure liposomal size is dynamic light scattering (DLS), which correlates the amount of scattered light to the mean size of the liposomes. The surface charge of liposomes affects not only their stability in solution, but also their adsorption into tissue, protein binding, and opsonization. Thus, the overall net charge of the particles, usually expressed as the surface or zeta potential, is another key feature of liposomal characterization. Nanoparticles with a zeta potential of at least 30 mV are considered stable, as they are charged enough to prevent aggregation. Additionally, higher zeta potential values lead to stronger membrane bindings and higher levels of cellular uptake [<xref rid="B88-pharmaceutics-17-00276" ref-type="bibr">88</xref>]. DLS can be employed to measure the zeta potential [<xref rid="B89-pharmaceutics-17-00276" ref-type="bibr">89</xref>].</p><p>In terms of drug loading and retention, encapsulation efficiency (EE) and in vitro drug release are the relevant characteristics. The EE is calculated as the percentage of the amount of the drug inside the liposomes compared to the total amount of the drug used in the liposome preparation. To determine the EE, the non-encapsulated free drug must first be separated from the liposomes. This can be achieved using various methods, including size exclusion chromatography, centrifugation or ultracentrifugation, and dialysis membrane with an appropriate cut-off. The next step is determining the amount of the encapsulated drug, either directly by measuring the amount of the drug in the liposomes or indirectly by measuring the free drug and subtracting it from the total drug used. Methods for assessing the concentration of the drug depend mostly on the drug molecule and range from UV&#x02013;Vis or fluorescence spectroscopy and protein-based assays to mass spectrometry [<xref rid="B90-pharmaceutics-17-00276" ref-type="bibr">90</xref>]. The in vitro drug release profile refers to the cumulative release percentage over time. It is measured using dialysis conditions&#x02014;the liposomes are placed in a dialysis bag membrane with a specific molecular cut-off. The bag is placed into a simulated physiological fluid kept at 37 &#x000b0;C to mimic an in vivo environment. At selected time points, the concentration of the released drug is measured [<xref rid="B91-pharmaceutics-17-00276" ref-type="bibr">91</xref>].</p></sec><sec id="sec2dot3-pharmaceutics-17-00276"><title>2.3. Cellular Internalization Mechanisms</title><p>The cellular internalization of liposomes is a complex process influenced by various factors, including liposome composition, size, charge, and the specific endocytic pathways utilized by the target cells. Liposomes can enter cells through several mechanisms, primarily endocytosis, which includes clathrin-mediated endocytosis, caveolae-mediated endocytosis, and micropinocytosis [<xref rid="B92-pharmaceutics-17-00276" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceutics-17-00276" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-17-00276" ref-type="bibr">94</xref>].</p><p>Cationic liposomes, which carry a positive charge, have been shown to enhance cellular uptake due to their favorable interactions with the negatively charged cell membranes. It was demonstrated that cationic liposomes effectively internalize into neutrophils via natural phagocytosis, facilitated by their positive zeta potential, which enhances the membrane interactions [<xref rid="B95-pharmaceutics-17-00276" ref-type="bibr">95</xref>]. Similarly, the work by Mudhakir et al. indicated that cationic liposomes are internalized efficiently through clathrin-mediated and caveolar endocytosis, highlighting the importance of the liposome charge in determining the uptake pathway [<xref rid="B96-pharmaceutics-17-00276" ref-type="bibr">96</xref>]. The size of the liposomes also plays a critical role in their internalization efficiency. Research by Sakai-Kato et al. indicated that liposomes with diameters around 100 nm are particularly effective for cellular uptake [<xref rid="B97-pharmaceutics-17-00276" ref-type="bibr">97</xref>]. This observation is supported by further findings that the diameter of the liposomes significantly influences their endocytic uptake, suggesting an optimal size for effective internalization [<xref rid="B98-pharmaceutics-17-00276" ref-type="bibr">98</xref>]. Furthermore, the functionalization of liposomes with targeting ligands can enhance their uptake through receptor-mediated endocytosis. Sun et al. illustrated that folate-functionalized liposomes bind to folate receptors on target cells, leading to efficient internalization via endosomal pathways [<xref rid="B99-pharmaceutics-17-00276" ref-type="bibr">99</xref>]. This targeted approach is further supported by the work of He et al., which demonstrated that gonadorelin-modified liposomes achieved a significantly higher uptake in target cells through specific receptor-mediated endocytosis than nonmodified liposomes [<xref rid="B100-pharmaceutics-17-00276" ref-type="bibr">100</xref>]. In addition to charge and size, the physicochemical properties of liposomes, such as membrane fluidity and rigidity, also affect their internalization. It was shown that increased membrane fluidity could enhance the endocytosis of phosphatidylserine-containing liposomes, while rigid liposomes may require more energy for effective internalization [<xref rid="B101-pharmaceutics-17-00276" ref-type="bibr">101</xref>]. This is consistent with findings from Takechi-Haraya et al., which emphasized the importance of liposome membrane characteristics in facilitating liposome uptake [<xref rid="B102-pharmaceutics-17-00276" ref-type="bibr">102</xref>].</p><p>In summary, the internalization of liposomes into cells is a multifaceted process influenced by their charges, sizes, surface modifications, and physicochemical properties. Understanding these factors is crucial for optimizing liposome design for targeted drug delivery applications.</p></sec></sec><sec id="sec3-pharmaceutics-17-00276"><title>3. Clinical Applications</title><p>Liposomes offer a compelling approach for drug delivery systems, particularly in oncology, where they can contribute to improved drug stability, targeted delivery, controlled release, and reduced toxicity. In recent years, several liposomal formulations have successfully progressed from pre-clinical research to the clinic, offering promising solutions for targeted drug delivery. This section highlights the liposomal-based therapies that have received regulatory approval (<xref rid="pharmaceutics-17-00276-t001" ref-type="table">Table 1</xref>) and those currently undergoing clinical trials (<xref rid="pharmaceutics-17-00276-t002" ref-type="table">Table 2</xref>). Notably, the described ongoing clinical trials evaluate new liposomal formulations for applications in chemotherapy, immunotherapy, and other treatment modalities, emphasizing their adaptability to a variety of medical treatments. By reviewing these developments and clinical experiences, we can better understand the clinical applicability of the liposomal formulations and identify the challenges that remain in advancing their use. Taken together, these developments reflect the growing confidence in liposomal technology, with the ongoing trials playing a key role in advancing their broader clinical applications.</p><sec id="sec3dot1-pharmaceutics-17-00276"><title>3.1. Approved Liposomal Therapeutics</title><p>The first liposomal formulation approved for clinical use was Doxil<sup>&#x000ae;</sup> in 1995 (named Caelyx<sup>&#x000ae;</sup> in Europe) [<xref rid="B7-pharmaceutics-17-00276" ref-type="bibr">7</xref>]. Doxil is a formulation of liposomes containing the cytostatic drug doxorubicin hydrochloride. Doxil liposomes are composed of hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and lipidated PEG. This composition results in a high phase transition temperature, forming a non-flexible bilayer at 37 &#x000b0;C. The liposomal surface is covered with PEG molecules, ensuring a longer circulation time [<xref rid="B103-pharmaceutics-17-00276" ref-type="bibr">103</xref>]. Doxorubicin loading is performed actively using a transmembrane gradient of ammonium sulfate, which results in more than 90% EE [<xref rid="B7-pharmaceutics-17-00276" ref-type="bibr">7</xref>]. Doxil was at first approved for AIDS-related Kaposi&#x02019;s sarcoma, and later for recurrent ovarian cancer, metastatic breast cancer, and multiple myeloma. Doxil has shown superior clinical performance compared to free doxorubicin and is still one of the most extensively used liposomal drugs; it accumulates more selectively in tumor tissue, minimizing the cardiotoxic effect of doxorubicin. The levels of accumulated doxorubicin were 4 to 16 times higher compared to the free doxorubicin administration. Additionally, the drug levels at the tumor tissue peaked between 3 to 7 days after administration [<xref rid="B104-pharmaceutics-17-00276" ref-type="bibr">104</xref>]. In spite of the overall superior tolerability of Doxil, two side effects not typical in the use of the free drug were observed. The first one is Palmar Plantar Erythrodysthesia (PPE), which shows up as redness, tenderness, and peeling of the skin and limits the dose of Doxil [<xref rid="B105-pharmaceutics-17-00276" ref-type="bibr">105</xref>]. The second is a complement activation-related pseudo-allergy (CARPA), an acute hypersensitivity or infusion reaction, which many nano-systems can provoke [<xref rid="B106-pharmaceutics-17-00276" ref-type="bibr">106</xref>].</p><p>Other liposomal formulations encapsulating similar anti-cancer drugs were developed soon after. In 1996, DaunoXome<sup>&#x000ae;</sup> was approved for the treatment of HIV-associated Kaposi&#x02019;s sarcoma with a formulation composed of non-PEGylated liposomes containing daunorubicin, a drug from the same family&#x02014;anthracyclines&#x02014;as doxorubicin [<xref rid="B107-pharmaceutics-17-00276" ref-type="bibr">107</xref>]. Similar to Doxil, DaunoXome also reduced cardiotoxicity and improved efficacy compared to the free drug. However, the response rates of Doxil are higher than those of DaunoXome, potentially due to Doxil&#x02019;s PEGylation resulting in longer circulation times [<xref rid="B108-pharmaceutics-17-00276" ref-type="bibr">108</xref>]. Myocet<sup>&#x000ae;</sup> is a formulation of doxorubicin encapsulated in non-PEGylated liposomes, which leads to a reduced incidence of PPE, but also to more rapid clearance of the liposomes. It was approved for metastatic breast cancer in 2000 in Europe [<xref rid="B109-pharmaceutics-17-00276" ref-type="bibr">109</xref>].</p><p>In the case of Mepact<sup>&#x000ae;</sup>, approved in 2004 for non-metastatic osteosarcoma, uptake by the mononuclear phagocyte system was not an unwanted effect. Mepact is a liposomal form of muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), which is an immunostimulating compound; it activates macrophages to become tumoricidal. Compared to the free MTP-PE, the liposomal form was more efficient at activating the monocytes, was retained longer in the target organs, and was less toxic due to its fast clearance from circulation by the phagocytic cells of the reticuloendothelial system, and thus a lower systemic exposure [<xref rid="B110-pharmaceutics-17-00276" ref-type="bibr">110</xref>].</p><p>Marqibo<sup>&#x000ae;</sup> was designed to overcome the sub-optimal pharmacokinetics and dose-related neurotoxicity of vincristine, a highly active cell cycle-dependent anti-cancer drug. The liposomal form achieved a longer plasma circulation time, increased tumor tissue delivery and accumulation, and slowed the release of vincristine in the tumor tissues. These features translated to higher efficacy and tolerability compared to the free vincristine [<xref rid="B111-pharmaceutics-17-00276" ref-type="bibr">111</xref>]. Marqibo was approved by the FDA in 2012 for the treatment of leukemia.</p><p>Similar benefits were observed with Onyvide<sup>&#x000ae;</sup>, the liposomal form of irinotecan. Irinotecan is an anti-cancer drug with a broad spectrum of activity and DNA topoisomerase 1 as its primary target. Irinotecan&#x02019;s pharmacology is complex and multistep, requiring activation of the prodrug by the liver enzymes [<xref rid="B112-pharmaceutics-17-00276" ref-type="bibr">112</xref>]. The liposomal encapsulation resulted in a longer circulation time and prolonged tumor exposure, leading to a smaller dose of the liposomal drug needed to achieve similar effects compared to the free drug [<xref rid="B113-pharmaceutics-17-00276" ref-type="bibr">113</xref>].</p><p>Vyxeos<sup>&#x000ae;</sup> is a formulation of cytarabine and daunorubicin at a 5:1 ratio. This ratio was pre-clinically determined to be optimally synergistic for this drug combination. When free drugs are injected, their initial ratios change within minutes and the synergistic effect might be diminished. The liposomal encapsulation ensures fixed-ratio drug delivery to the target tumor tissue, in addition to other advantages of the liposomal systems [<xref rid="B114-pharmaceutics-17-00276" ref-type="bibr">114</xref>]. Treatment with Vyxeos was associated with longer survival compared to the standard-of-care cytarabine plus daunorubicin chemotherapy [<xref rid="B115-pharmaceutics-17-00276" ref-type="bibr">115</xref>]. Vyxeos was approved for the treatment of acute myeloid leukemia in 2017.</p><p>In contrast to other marketed liposomal anti-cancer drugs, Depocyt<sup>&#x000ae;</sup> is composed of multivesicular liposomes, which are associated with higher stability and slower drug release compared to standard unilamellar vesicles. Depocyt was approved in 1999 for the treatment of neoplastic meningitis. A significant obstacle in the treatment of neoplastic meningitis is the poor penetration of systemically administered chemotherapeutics into the cerebrospinal fluid. Intrathecal injection is thus the preferred treatment; however, the half-life of cytarabine is short, while its mechanism demands prolonged exposure. A sustained release formulation using multivesicular liposomes was developed to overcome this. Treatment with Depocyt was associated with a longer time of survival and fewer adverse side effects, with an additional advantage of less frequent dosing [<xref rid="B116-pharmaceutics-17-00276" ref-type="bibr">116</xref>].</p></sec><sec id="sec3dot2-pharmaceutics-17-00276"><title>3.2. Selected Liposomal Formulations in Clinical Trials</title><p>Numerous novel liposome formulation-based therapies for cancer treatment have been developed and are undergoing clinical trials for the evaluation of their safety, dosage, and effectiveness, with applications spanning chemotherapy, immunotherapy, and radiotherapy, among many others (<xref rid="pharmaceutics-17-00276-t002" ref-type="table">Table 2</xref>).</p><p>The first approved Doxil<sup>&#x000ae;</sup>/Caelyx<sup>&#x000ae;</sup> lipid formulation, composed of hydrogenated soybean phosphatidylcholine (HSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (MPEG2000-DSPE), and cholesterol, is currently being evaluated in several phase II and III clinical trials for treating a variety of cancers, including triple-negative breast cancer (clinicaltrials.gov, NCT03971409) and recurrent ovarian cancer (clinicaltrials.gov, NCT06014528, NCT02839707, NCT00326456), in combination with agents such as avelumab, binimetinib, atezolizumab, and carboplatin. Different formulations of encapsulated doxorubicin have been developed over the years, with significant modifications made to the lipid composition, thermostability, liposomal size, and charge, achieving superior drug entrapment efficiencies, prolonged stable storage, higher release performance and circulation times, and reduced uptake by vital organs [<xref rid="B117-pharmaceutics-17-00276" ref-type="bibr">117</xref>]. For instance, Talidox<sup>&#x000ae;</sup>, a new liposomal doxorubicin formulation currently undergoing a clinical trial in advanced solid tumors (clinicaltrials.gov, NCT03387917), has been designed with a particle size twice as small as conventional liposomal formulations, thus enabling deeper penetration into tumors [<xref rid="B118-pharmaceutics-17-00276" ref-type="bibr">118</xref>].</p><p>Besides doxorubicin, other chemotherapeutic drugs have been applied to liposomal formulation and drug delivery. Topotecan, a small molecule drug and topoisomerase inhibitor encapsulated in a liposomal formulation [<xref rid="B119-pharmaceutics-17-00276" ref-type="bibr">119</xref>] composed of dihydrosphingomyelin (DHSM), cholesterol, and polyethylene glycol (FF-10850), is undergoing a phase I trial (clinicaltrials.gov, NCT04047251) to assess its safety in treating advanced solid tumors such as Merkel cell carcinoma [<xref rid="B120-pharmaceutics-17-00276" ref-type="bibr">120</xref>]. Irinotecan, another topoisomerase inhibitor [<xref rid="B119-pharmaceutics-17-00276" ref-type="bibr">119</xref>], is encapsulated in the Nal-IRI (Onivyde<sup>&#x000ae;</sup>) liposomal formulation, composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and MPEG2000-DSPE [<xref rid="B121-pharmaceutics-17-00276" ref-type="bibr">121</xref>] and currently undergoing a phase III trial for advanced pancreatic cancer (clinicaltrials.gov, NCT03468335). This formulation is being tested in combination with fluorouracil and leucovorin as a second-line therapy. Additionally, CPX-351 (Vyxeos<sup>&#x000ae;</sup>) is a phase II liposomal formulation of DSPC, 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG), and cholesterol. These liposomes encapsulate two chemotherapeutic agents, daunorubicin and cytarabine (clinicaltrials.gov, NCT04269213), and are being tested for the treatment of secondary acute myeloid leukemia in patients younger than 60 years old, both as a monotherapy and in combination with ruxolitinib [<xref rid="B122-pharmaceutics-17-00276" ref-type="bibr">122</xref>].</p><p>In parallel with small molecule drug delivery, liposomal nanoparticles also show great promise in cancer immunotherapy, including vaccines. For instance, nanoparticles enhance the effectiveness of cancer vaccines by ensuring prolonged persistence in tissues as well as the controlled release of antigens and adjuvants [<xref rid="B123-pharmaceutics-17-00276" ref-type="bibr">123</xref>]. One such example is the autologous tumor mRNA-loaded liposome vaccine, composed of cationic lipid DOTAP, which has been studied for its ability to induce immune responses against melanoma (clinicaltrials.gov, NCT05264974) [<xref rid="B124-pharmaceutics-17-00276" ref-type="bibr">124</xref>]. In addition to their role in cancer vaccines, liposomal formulations are increasingly used in cancer immunotherapy to enhance drug delivery, modulate the immune response, and improve the therapeutic efficacy of approaches such as immune checkpoint blockade and cancer vaccines [<xref rid="B125-pharmaceutics-17-00276" ref-type="bibr">125</xref>]. In line with this, HF1K16 is a phase I investigational liposomal formulation of all-trans retinoic acid (ATRA) utilizing HSPC and MPEG-DSPE, designed for sustained drug release to target solid tumors by promoting MDSC maturation and modifying the tumor microenvironment to enhance immune responses (clinicaltrials.gov, NCT05388487) [<xref rid="B126-pharmaceutics-17-00276" ref-type="bibr">126</xref>].</p><p>Liposomal formulations are also used to encapsulate antisense oligonucleotides (ASOs) for cancer treatment, as they facilitate efficient drug distribution, improve cellular uptake, and allow the ASOs to bypass the endocytic degradation process, ensuring a more effective delivery to the target tumor cells [<xref rid="B127-pharmaceutics-17-00276" ref-type="bibr">127</xref>]. In this context, BP1002, a phase I liposomal formulation containing an antisense oligonucleotide targeting the Bcl-2 transcript (clinicaltrials.gov, NCT05190471), is being tested for the treatment of refractory or relapsed acute myeloid leukemia. The critical role of the pro-survival and pro-apoptotic Bcl-2 family oncoproteins in the regulation of apoptosis makes them attractive targets for the treatment of cancer [<xref rid="B128-pharmaceutics-17-00276" ref-type="bibr">128</xref>]. The BP1002 liposomes, formed from 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), are being evaluated in combination with venetoclax and decitabine to improve future treatment outcomes [<xref rid="B129-pharmaceutics-17-00276" ref-type="bibr">129</xref>].</p><p>These examples demonstrate the continued exploration and potential of liposomal therapies to enhance drug delivery, reduce side effects, and improve efficacy in treating both solid tumors and hematological malignancies.</p><table-wrap position="anchor" id="pharmaceutics-17-00276-t001"><object-id pub-id-type="pii">pharmaceutics-17-00276-t001_Table 1</object-id><label>Table 1</label><caption><p>Liposomal formulations approved for clinics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Agent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lipid Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Injection Route</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Company</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup> (US)<break/>Caelyx<sup>&#x000ae;</sup> (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995 (US)<break/>1996 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPEG-DSPE, HSPC, cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic ovarian carcinoma, AIDS-related Kaposi&#x02019;s sarcoma, multiple myeloma, breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baxter Healthcare Corporation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DaunoXome<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996 (US)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIDS-related Kaposi&#x02019;s sarcoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NexStar Pharmaceuticals</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DepoCyt<sup>&#x000ae;</sup> (US, EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1999 (US)<break/>2001 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol, triolein, DOPC, DPPG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intrathecal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphomatous meningitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pacira Pharmaceuticals</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocet<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphatidylcholine, cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheplapharm Arzneimittel</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mepact<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTP-PE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POPC, OOPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-metastatic osteosarcoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Takeda France</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marqibo<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012 (US)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vincristine sulfate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sphingomyelin, cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute lymphoblastic leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Talon Pharmaceuticals</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onivyde<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015 (US)<break/>2016 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol, MPEG2000-DSPE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic pancreatic adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merrimack Pharmaceuticals</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vyxeos<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017 (US)<break/>2018 (EU)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin, cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, DSPG, cholesterol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Celator Pharmaceuticals</td></tr></tbody></table><table-wrap-foot><fn><p>DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; DPPG: dipalmitoylphosphatidylglycerol; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPG: 1,2-distearoyl-sn-glycero-3-phosphoglycerol; HSPC: hydrogenated soybean phosphatidylcholine; MPEG-DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]; MPEG2000-DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; OOPS: 1,2-dioleoyl-sn-glycero-3-phospho-L-serine monosodium salt; POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="anchor" id="pharmaceutics-17-00276-t002"><object-id pub-id-type="pii">pharmaceutics-17-00276-t002_Table 2</object-id><label>Table 2</label><caption><p>Liposomes under different phases of clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lipid Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NTC Number</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FF-10850</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DHSM, cholesterol, polyethylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced solid tumors (Merkel cell carcinoma)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fujifilm Pharmaceuticals U.S.A., Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04047251<break/>[<xref rid="B120-pharmaceutics-17-00276" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FF-10832</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol, HSPC, N-MPEG-DSPE (4:15:1) [<xref rid="B130-pharmaceutics-17-00276" ref-type="bibr">130</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced solid tumors, biliary tract cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fujifilm Pharmaceuticals U.S.A., Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03440450<break/>[<xref rid="B131-pharmaceutics-17-00276" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FF-10832</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholesterol, HSPC, MPEG-DSPE (4:15:1) [<xref rid="B130-pharmaceutics-17-00276" ref-type="bibr">130</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urothelial and non-small cell lung cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with pembrolizumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fujifilm Pharmaceuticals U.S.A., Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05318573<break/>[<xref rid="B132-pharmaceutics-17-00276" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186RNL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhenium-186</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol, (55:45) [<xref rid="B133-pharmaceutics-17-00276" ref-type="bibr">133</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignant glioma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plus Therapeutics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01906385<break/>[<xref rid="B134-pharmaceutics-17-00276" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLD-1 (Talidox<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol, MPEG-DSPE (58:37:5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swiss Group for Clinical Cancer Research</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03387917<break/>[<xref rid="B118-pharmaceutics-17-00276" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THE001 (DPPG2-TSL-DOX)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined with hyperthermia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thermosome GmbH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05858710</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup>/Caelyx<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, MPEG2000-DSPE, cholesterol (56.2:38.3:5) [<xref rid="B135-pharmaceutics-17-00276" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Triple-negative breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with avelumab and/or without binimetinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hope Rugo, MD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03971409</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup>/Caelyx<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, MPEG2000-DSPE, cholesterol (56.2:38.3:5) [<xref rid="B135-pharmaceutics-17-00276" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In combination with IN10018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inxmed (Shanghai) Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT06014528</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup>/Caelyx<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, MPEG2000-DSPE, cholesterol (56.2:38.3:5) [<xref rid="B135-pharmaceutics-17-00276" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent ovarian, peritoneal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with atezolizumab and/or bevacizumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Institute (NCI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02839707</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup>/Caelyx<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, MPEG2000-DSPE, cholesterol (56.2:38.3:5) [<xref rid="B135-pharmaceutics-17-00276" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Cancer Institute, Naples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT00326456</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thermo-Dox<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPC, MSPC, MEG2000-DSPE (86:10:4) [<xref rid="B136-pharmaceutics-17-00276" ref-type="bibr">136</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relapsed solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with hyperthermia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children&#x02019;s National Research Institute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04791228</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HF1K16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All-trans retinoic acid (ATRA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, MPEG2000-DSPE [<xref rid="B137-pharmaceutics-17-00276" ref-type="bibr">137</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highfield Biopharmaceuticals Corporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05388487<break/>[<xref rid="B126-pharmaceutics-17-00276" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CPX-351 (Vyxeos<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin and cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, DSPG, cholesterol (7:2:1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced-phase myeloproliferative neoplasms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ohio State University Comprehensive Cancer Center</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03878199<break/>[<xref rid="B115-pharmaceutics-17-00276" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CPX-351 (Vyxeos<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin and cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, DSPG, cholesterol (7:2:1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with ruxolitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roswell Park Cancer Institute</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04269213<break/>[<xref rid="B122-pharmaceutics-17-00276" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nal-IRI (Onivyde<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol, MPEG2000-DSPE (3:2:0,015) [<xref rid="B121-pharmaceutics-17-00276" ref-type="bibr">121</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECOG-ACRIN Cancer Research Group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04233866<break/>[<xref rid="B138-pharmaceutics-17-00276" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nal-IRI (Onivyde<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC, cholesterol, MPEG2000-DSPE (3:2:0,015) [<xref rid="B121-pharmaceutics-17-00276" ref-type="bibr">121</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with fluorouracil, leucovorin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AIO-Studien-gGmbH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03468335</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E7389-LF
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eribulin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, cholesterol, MPEG2000-DSPE [<xref rid="B139-pharmaceutics-17-00276" ref-type="bibr">139</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy and in combination with nivolumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eisai Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03207672<break/>NCT04078295<break/>[<xref rid="B140-pharmaceutics-17-00276" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceutics-17-00276" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitoxantrone liposome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitoxantrone hydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, cholesterol, MPEG-DSPE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic nasopharyngeal carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In combination with PD-1 blockade</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ming-Yuan Chen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT06472713</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitoxantrone liposome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitoxantrone hydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, cholesterol, MPEG-DSPE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic nasopharyngeal carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CSPC Zhongnuo Pharmaceutical Co., Ltd.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05717764</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-ANN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annamycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NDLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moleculin Biotech, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05319587<break/>[<xref rid="B142-pharmaceutics-17-00276" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SMP-3124LP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHK1 (checkpoint kinase 1) inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NDLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In combination with cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sumitomo Pharma America, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT06526819<break/>[<xref rid="B143-pharmaceutics-17-00276" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-TC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trans-crocetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, cholesterol, MPEG2000-DSPE (6:2:1) [<xref rid="B144-pharmaceutics-17-00276" ref-type="bibr">144</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Institut de canc&#x000e9;rologie Strasbourg Europe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT06477939</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BP1001<break/>BP1002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antisense oligodeoxynucleotide against GRB2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOPC [<xref rid="B129-pharmaceutics-17-00276" ref-type="bibr">129</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy and in combination with ventoclax, decitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bio-Path Holdings, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02781883 NCT05190471<break/>[<xref rid="B145-pharmaceutics-17-00276" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promitil<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitomycin-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSPC, cholesterol, MPEG2000-DSPE (11:6:1) [<xref rid="B146-pharmaceutics-17-00276" ref-type="bibr">146</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic and ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy and in combination with decitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipomedix Pharmaceuticals Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT06478862</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visudyne<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Verteporfin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egg PG, DMPC, ascorbyl palmitate, butylated hydroxytoluene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma, recurrent glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">William Read, Emory University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT04590664<break/>[<xref rid="B147-pharmaceutics-17-00276" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC (Lipo-Curc<sup>&#x000ae;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DMPC (72 mg/mL), DMPG (8 mg/mL) [<xref rid="B148-pharmaceutics-17-00276" ref-type="bibr">148</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Signpath Pharma, Inc.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05768919<break/>[<xref rid="B149-pharmaceutics-17-00276" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDS0101</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV-targeted immunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOTAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Papillomavirus-associated oropharynx cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with radiotherapy and temozolomide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayo Clinic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05232851<break/>[<xref rid="B150-pharmaceutics-17-00276" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor mRNA liposome vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pp65 full length LAMP1 mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DOTAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination with capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University of Florida</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT05264974<break/>[<xref rid="B124-pharmaceutics-17-00276" ref-type="bibr">124</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>DHSM: dihydrosphingomyelin; DMPG: 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol; DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; PG: phosphatidylglycerol; DPPG: 1,2-dipalmitoyl-sn-glycero-3-phosphor-(10 -rac-glycerol); DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DSPG: 1,2-distearoyl-sn-glycero-3-phosphoglycerol; HSPC: hydrogenated soybean phosphatidylcholine; MPEG-DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]; MSPC: 1-stearoyl-2-hydroxy-sn-glycero-3-phosphatidylcholine; MPEG2000-DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; NDLC: not defined lipid composition. The lipid compositions are provided as molar ratios.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00276"><title>4. Conclusions</title><p>In summary, liposome-based targeted drug delivery systems mark a significant advancement in pharmaceutical science, offering distinct advantages that enhance both the efficacy and safety of various therapies. Their biocompatibility and ability to encapsulate diverse drug types, both hydrophilic and hydrophobic, make liposomes highly versatile carriers in clinical settings. This review underscores how liposomal formulations have improved drug pharmacokinetics while reducing side effects, particularly in oncology, where targeted delivery specifically to the tumor cells is crucial.</p><p>Multiple clinical trials have solidified the role of liposomes in modern medicine, with several formulations receiving regulatory approval and becoming vital components of established treatment protocols. These advancements highlight not only the promise of liposomes across multiple therapeutic approaches as monotherapies, but also their potential for synergistic approaches with other standard-of-care approved drugs in combination therapies.</p><p>Although liposomal drug delivery systems hold significant promise for clinical use, there are several challenges preventing their more extensive implementation and regulatory approval. One key issue is the complexity and variability in the manufacturing process, which may require additional efforts to optimize the methods and ensure consistent product quality and performance. Regulatory agencies require rigorous, reproducible data to demonstrate safety, efficacy, and quality, but the complexity of liposome production often makes it challenging to meet these standards, requiring continuous optimization for consistency [<xref rid="B151-pharmaceutics-17-00276" ref-type="bibr">151</xref>]. While liposomes offer targeted delivery, their behavior in the body can be unpredictable, with factors like size, lipid composition, surface charge, and targeting and release mechanisms of actions influencing their effectiveness. Additionally, there is still limited knowledge about their long-term pharmacokinetics and potential immunogenicity, raising concerns about their safety over time. High production costs and the need for extensive clinical trials to confirm therapeutic benefits further complicate their use [<xref rid="B56-pharmaceutics-17-00276" ref-type="bibr">56</xref>,<xref rid="B151-pharmaceutics-17-00276" ref-type="bibr">151</xref>]. Addressing these issues requires ongoing advancements in liposome technology, clearer regulatory pathways, and a deeper understanding of their clinical behavior across different treatments.</p><p>Future research thus should prioritize advancements in the targeting mechanisms through innovative surface modifications and the exploration of novel drug combinations to address the complexities of multifactorial diseases. With a deeper understanding of how liposomes interact with biological systems and improvement of their biochemical properties, we expect to see exciting developments that can broaden their applications. Ultimately, liposome-based drug delivery systems have the potential to transform therapeutic approaches, paving the way for more effective and personalized treatments for patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Author Olga Vasiljeva was employed by the company CytomX Therapeutics.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00276"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>B.Y.</given-names></name>
<name><surname>Rutka</surname><given-names>J.T.</given-names></name>
<name><surname>Chan</surname><given-names>W.C.</given-names></name>
</person-group><article-title>Nanomedicine</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>2434</fpage><lpage>2443</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0912273</pub-id><pub-id pub-id-type="pmid">21158659</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00276"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagathihalli</surname><given-names>N.S.</given-names></name>
<name><surname>Castellanos</surname><given-names>J.A.</given-names></name>
<name><surname>Shi</surname><given-names>C.</given-names></name>
<name><surname>Beesetty</surname><given-names>Y.</given-names></name>
<name><surname>Reyzer</surname><given-names>M.L.</given-names></name>
<name><surname>Caprioli</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Walsh</surname><given-names>A.J.</given-names></name>
<name><surname>Skala</surname><given-names>M.C.</given-names></name>
<name><surname>Moses</surname><given-names>H.L.</given-names></name>
<etal/>
</person-group><article-title>Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>1932</fpage><lpage>1943.e9</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.07.058</pub-id><pub-id pub-id-type="pmid">26255562</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00276"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raj</surname><given-names>S.</given-names></name>
<name><surname>Khurana</surname><given-names>S.</given-names></name>
<name><surname>Choudhari</surname><given-names>R.</given-names></name>
<name><surname>Kesari</surname><given-names>K.K.</given-names></name>
<name><surname>Kamal</surname><given-names>M.A.</given-names></name>
<name><surname>Garg</surname><given-names>N.</given-names></name>
<name><surname>Ruokolainen</surname><given-names>J.</given-names></name>
<name><surname>Das</surname><given-names>B.C.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy</article-title><source>Semin. Cancer Biol.</source><year>2021</year><volume>69</volume><fpage>166</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.11.002</pub-id><pub-id pub-id-type="pmid">31715247</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00276"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perez-Herrero</surname><given-names>E.</given-names></name>
<name><surname>Fernandez-Medarde</surname><given-names>A.</given-names></name>
</person-group><article-title>Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>93</volume><fpage>52</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.03.018</pub-id><pub-id pub-id-type="pmid">25813885</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00276"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elbayoumi</surname><given-names>T.A.</given-names></name>
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Current trends in liposome research</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>605</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-360-2_1</pub-id><pub-id pub-id-type="pmid">20072870</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00276"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bangham</surname><given-names>A.D.</given-names></name>
<name><surname>Standish</surname><given-names>M.M.</given-names></name>
<name><surname>Watkins</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Diffusion of univalent ions across the lamellae of swollen phospholipids</article-title><source>J. Mol. Biol.</source><year>1965</year><volume>13</volume><fpage>238</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(65)80093-6</pub-id><pub-id pub-id-type="pmid">5859039</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00276"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barenholz</surname><given-names>Y.</given-names></name>
</person-group><article-title>Doxil(r)&#x02013;the first fda-approved nano-drug: Lessons learned</article-title><source>J. Control. Release</source><year>2012</year><volume>160</volume><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.03.020</pub-id><pub-id pub-id-type="pmid">22484195</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00276"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bulbake</surname><given-names>U.</given-names></name>
<name><surname>Doppalapudi</surname><given-names>S.</given-names></name>
<name><surname>Kommineni</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Liposomal formulations in clinical use: An updated review</article-title><source>Pharmaceutics</source><year>2017</year><volume>9</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics9020012</pub-id><pub-id pub-id-type="pmid">28346375</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00276"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>B.</given-names></name>
<name><surname>Geetha</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Lipid nanoparticles in the development of mrna vaccines for COVID-19</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2022</year><volume>74</volume><fpage>103553</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103553</pub-id><pub-id pub-id-type="pmid">35783677</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00276"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pattni</surname><given-names>B.S.</given-names></name>
<name><surname>Chupin</surname><given-names>V.V.</given-names></name>
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>New developments in liposomal drug delivery</article-title><source>Chem. Rev.</source><year>2015</year><volume>115</volume><fpage>10938</fpage><lpage>10966</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00046</pub-id><pub-id pub-id-type="pmid">26010257</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00276"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvagno</surname><given-names>M.G.</given-names></name>
<name><surname>Celia</surname><given-names>C.</given-names></name>
<name><surname>Paolino</surname><given-names>D.</given-names></name>
<name><surname>Cosco</surname><given-names>D.</given-names></name>
<name><surname>Iannone</surname><given-names>M.</given-names></name>
<name><surname>Castelli</surname><given-names>F.</given-names></name>
<name><surname>Doldo</surname><given-names>P.</given-names></name>
<name><surname>Frest</surname><given-names>M.</given-names></name>
</person-group><article-title>Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes</article-title><source>Curr. Drug Deliv.</source><year>2007</year><volume>4</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.2174/156720107779314749</pub-id><pub-id pub-id-type="pmid">17269921</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00276"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Briuglia</surname><given-names>M.L.</given-names></name>
<name><surname>Rotella</surname><given-names>C.</given-names></name>
<name><surname>McFarlane</surname><given-names>A.</given-names></name>
<name><surname>Lamprou</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Influence of cholesterol on liposome stability and on in vitro drug release</article-title><source>Drug Deliv. Transl. Res.</source><year>2015</year><volume>5</volume><fpage>231</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/s13346-015-0220-8</pub-id><pub-id pub-id-type="pmid">25787731</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00276"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bangham</surname><given-names>A.D.</given-names></name>
</person-group><article-title>A correlation between surface charge and coagulant action of phospholipids</article-title><source>Nature</source><year>1961</year><volume>192</volume><fpage>1197</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1038/1921197a0</pub-id><pub-id pub-id-type="pmid">13864660</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00276"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senior</surname><given-names>J.</given-names></name>
<name><surname>Gregoriadis</surname><given-names>G.</given-names></name>
</person-group><article-title>Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components</article-title><source>Life Sci.</source><year>1982</year><volume>30</volume><fpage>2123</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(82)90455-6</pub-id><pub-id pub-id-type="pmid">7109841</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00276"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>San</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Z.Y.</given-names></name>
<name><surname>Pompili</surname><given-names>V.J.</given-names></name>
<name><surname>Jaffe</surname><given-names>M.L.</given-names></name>
<name><surname>Plautz</surname><given-names>G.E.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Felgner</surname><given-names>J.H.</given-names></name>
<name><surname>Wheeler</surname><given-names>C.J.</given-names></name>
<name><surname>Felgner</surname><given-names>P.L.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy</article-title><source>Hum. Gene Ther.</source><year>1993</year><volume>4</volume><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1089/hum.1993.4.6-781</pub-id><pub-id pub-id-type="pmid">8186291</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00276"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Youn</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Furgeson</surname><given-names>D.Y.</given-names></name>
</person-group><article-title>A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted sirna delivery</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1021/mp400446v</pub-id><pub-id pub-id-type="pmid">24387132</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00276"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonzalez-Rodriguez</surname><given-names>M.L.</given-names></name>
<name><surname>Rabasco</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Charged liposomes as carriers to enhance the permeation through the skin</article-title><source>Expert Opin. Drug Deliv.</source><year>2011</year><volume>8</volume><fpage>857</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1517/17425247.2011.574610</pub-id><pub-id pub-id-type="pmid">21557706</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00276"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>T.M.</given-names></name>
</person-group><article-title>The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system</article-title><source>Adv. Drug Deliv. Rev.</source><year>1994</year><volume>13</volume><fpage>285</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/0169-409X(94)90016-7</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00276"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papahadjopoulos</surname><given-names>D.</given-names></name>
<name><surname>Allen</surname><given-names>T.M.</given-names></name>
<name><surname>Gabizon</surname><given-names>A.</given-names></name>
<name><surname>Mayhew</surname><given-names>E.</given-names></name>
<name><surname>Matthay</surname><given-names>K.</given-names></name>
<name><surname>Huang</surname><given-names>S.K.</given-names></name>
<name><surname>Lee</surname><given-names>K.D.</given-names></name>
<name><surname>Woodle</surname><given-names>M.C.</given-names></name>
<name><surname>Lasic</surname><given-names>D.D.</given-names></name>
<name><surname>Redemann</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1991</year><volume>88</volume><fpage>11460</fpage><lpage>11464</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.24.11460</pub-id><pub-id pub-id-type="pmid">1763060</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00276"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumura</surname><given-names>Y.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
</person-group><article-title>A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><issue-part>Pt 1</issue-part><fpage>6387</fpage><lpage>6392</lpage><pub-id pub-id-type="pmid">2946403</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00276"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomitaka</surname><given-names>A.</given-names></name>
<name><surname>Takemura</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Roy</surname><given-names>U.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
</person-group><article-title>Magnetoliposomes in controlled-release drug delivery systems</article-title><source>Crit. Rev. Biomed. Eng.</source><year>2019</year><volume>47</volume><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1615/CritRevBiomedEng.2020033002</pub-id><pub-id pub-id-type="pmid">32421974</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00276"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mikhaylov</surname><given-names>G.</given-names></name>
<name><surname>Mikac</surname><given-names>U.</given-names></name>
<name><surname>Magaeva</surname><given-names>A.A.</given-names></name>
<name><surname>Itin</surname><given-names>V.I.</given-names></name>
<name><surname>Naiden</surname><given-names>E.P.</given-names></name>
<name><surname>Psakhye</surname><given-names>I.</given-names></name>
<name><surname>Babes</surname><given-names>L.</given-names></name>
<name><surname>Reinheckel</surname><given-names>T.</given-names></name>
<name><surname>Peters</surname><given-names>C.</given-names></name>
<name><surname>Zeiser</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Ferri-liposomes as an mri-visible drug-delivery system for targeting tumours and their microenvironment</article-title><source>Nat. Nanotechnol.</source><year>2011</year><volume>6</volume><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nnano.2011.112</pub-id><pub-id pub-id-type="pmid">21822252</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00276"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wicki</surname><given-names>A.</given-names></name>
<name><surname>Witzigmann</surname><given-names>D.</given-names></name>
<name><surname>Balasubramanian</surname><given-names>V.</given-names></name>
<name><surname>Huwyler</surname><given-names>J.</given-names></name>
</person-group><article-title>Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications</article-title><source>J. Control. Release</source><year>2015</year><volume>200</volume><fpage>138</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.12.030</pub-id><pub-id pub-id-type="pmid">25545217</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00276"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawant</surname><given-names>R.R.</given-names></name>
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Challenges in development of targeted liposomal therapeutics</article-title><source>AAPS J.</source><year>2012</year><volume>14</volume><fpage>303</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9330-0</pub-id><pub-id pub-id-type="pmid">22415612</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00276"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paszko</surname><given-names>E.</given-names></name>
<name><surname>Senge</surname><given-names>M.O.</given-names></name>
</person-group><article-title>Immunoliposomes</article-title><source>Curr. Med. Chem.</source><year>2012</year><volume>19</volume><fpage>5239</fpage><lpage>5277</lpage><pub-id pub-id-type="doi">10.2174/092986712803833362</pub-id><pub-id pub-id-type="pmid">22934774</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00276"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregoriadis</surname><given-names>E.G.</given-names></name>
<name><surname>Neerunjun</surname><given-names>D.</given-names></name>
</person-group><article-title>Homing of liposomes to target cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1975</year><volume>65</volume><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(75)80180-X</pub-id><pub-id pub-id-type="pmid">50067</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00276"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leserman</surname><given-names>L.D.</given-names></name>
<name><surname>Machy</surname><given-names>P.</given-names></name>
<name><surname>Barbet</surname><given-names>J.</given-names></name>
</person-group><article-title>Cell-specific drug transfer from liposomes bearing monoclonal antibodies</article-title><source>Nature</source><year>1981</year><volume>293</volume><fpage>226</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/293226a0</pub-id><pub-id pub-id-type="pmid">7278980</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00276"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>J.W.</given-names></name>
<name><surname>Hong</surname><given-names>K.</given-names></name>
<name><surname>Kirpotin</surname><given-names>D.B.</given-names></name>
<name><surname>Meyer</surname><given-names>O.</given-names></name>
<name><surname>Papahadjopoulos</surname><given-names>D.</given-names></name>
<name><surname>Benz</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Anti-her2 immunoliposomes for targeted therapy of human tumors</article-title><source>Cancer Lett.</source><year>1997</year><volume>118</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(97)00326-1</pub-id><pub-id pub-id-type="pmid">9459205</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00276"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrilli</surname><given-names>R.</given-names></name>
<name><surname>Eloy</surname><given-names>J.O.</given-names></name>
<name><surname>Lopez</surname><given-names>R.F.</given-names></name>
<name><surname>Lee</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Cetuximab immunoliposomes enhance delivery of 5-fu to skin squamous carcinoma cells</article-title><source>Anticancer Agents Med. Chem.</source><year>2017</year><volume>17</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.2174/1871520616666160526110913</pub-id><pub-id pub-id-type="pmid">27225449</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00276"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zalba</surname><given-names>S.</given-names></name>
<name><surname>Contreras</surname><given-names>A.M.</given-names></name>
<name><surname>Haeri</surname><given-names>A.</given-names></name>
<name><surname>Ten Hagen</surname><given-names>T.L.</given-names></name>
<name><surname>Navarro</surname><given-names>I.</given-names></name>
<name><surname>Koning</surname><given-names>G.</given-names></name>
<name><surname>Garrido</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer</article-title><source>J. Control. Release</source><year>2015</year><volume>210</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.05.271</pub-id><pub-id pub-id-type="pmid">25998052</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00276"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yue</surname><given-names>P.J.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Qiu</surname><given-names>S.W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liao</surname><given-names>Y.J.</given-names></name>
<name><surname>Li</surname><given-names>X.P.</given-names></name>
<name><surname>Xie</surname><given-names>D.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
</person-group><article-title>Ox26/ctx-conjugated pegylated liposome as a dual-targeting gene delivery system for brain glioma</article-title><source>Mol. Cancer</source><year>2014</year><volume>13</volume><fpage>191</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-13-191</pub-id><pub-id pub-id-type="pmid">25128329</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00276"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Zhong</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Zou</surname><given-names>H.</given-names></name>
<name><surname>Kou</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Tumor-targeted pe38kdel delivery via pegylated anti-her2 immunoliposomes</article-title><source>Int. J. Pharm.</source><year>2009</year><volume>374</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2009.03.018</pub-id><pub-id pub-id-type="pmid">19446771</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00276"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mikhaylov</surname><given-names>G.</given-names></name>
<name><surname>Klimpel</surname><given-names>D.</given-names></name>
<name><surname>Schaschke</surname><given-names>N.</given-names></name>
<name><surname>Mikac</surname><given-names>U.</given-names></name>
<name><surname>Vizovisek</surname><given-names>M.</given-names></name>
<name><surname>Fonovic</surname><given-names>M.</given-names></name>
<name><surname>Turk</surname><given-names>V.</given-names></name>
<name><surname>Turk</surname><given-names>B.</given-names></name>
<name><surname>Vasiljeva</surname><given-names>O.</given-names></name>
</person-group><article-title>Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin b inhibitor</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><fpage>10077</fpage><lpage>10081</lpage><pub-id pub-id-type="doi">10.1002/anie.201402305</pub-id><pub-id pub-id-type="pmid">24975267</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00276"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bratovs</surname><given-names>A.</given-names></name>
<name><surname>Kramer</surname><given-names>L.</given-names></name>
<name><surname>Mikhaylov</surname><given-names>G.</given-names></name>
<name><surname>Vasiljeva</surname><given-names>O.</given-names></name>
<name><surname>Turk</surname><given-names>B.</given-names></name>
</person-group><article-title>Stefin a-functionalized liposomes as a system for cathepsins s and l-targeted drug delivery</article-title><source>Biochimie</source><year>2019</year><volume>166</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2019.05.018</pub-id><pub-id pub-id-type="pmid">31163196</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00276"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kozak</surname><given-names>A.</given-names></name>
<name><surname>Mikhaylov</surname><given-names>G.</given-names></name>
<name><surname>Khodakivskyi</surname><given-names>P.</given-names></name>
<name><surname>Goun</surname><given-names>E.</given-names></name>
<name><surname>Turk</surname><given-names>B.</given-names></name>
<name><surname>Vasiljeva</surname><given-names>O.</given-names></name>
</person-group><article-title>A new cathepsin d targeting drug delivery system based on immunoliposomes functionalized with lipidated pepstatin A</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2464</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15102464</pub-id><pub-id pub-id-type="pmid">37896224</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00276"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gosk</surname><given-names>S.</given-names></name>
<name><surname>Moos</surname><given-names>T.</given-names></name>
<name><surname>Gottstein</surname><given-names>C.</given-names></name>
<name><surname>Bendas</surname><given-names>G.</given-names></name>
</person-group><article-title>Vcam-1 directed immunoliposomes selectively target tumor vasculature in vivo</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1778</volume><fpage>854</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.12.021</pub-id><pub-id pub-id-type="pmid">18211818</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00276"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiffelers</surname><given-names>R.M.</given-names></name>
<name><surname>Koning</surname><given-names>G.A.</given-names></name>
<name><surname>ten Hagen</surname><given-names>T.L.</given-names></name>
<name><surname>Fens</surname><given-names>M.H.</given-names></name>
<name><surname>Schraa</surname><given-names>A.J.</given-names></name>
<name><surname>Janssen</surname><given-names>A.P.</given-names></name>
<name><surname>Kok</surname><given-names>R.J.</given-names></name>
<name><surname>Molema</surname><given-names>G.</given-names></name>
<name><surname>Storm</surname><given-names>G.</given-names></name>
</person-group><article-title>Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin</article-title><source>J. Control. Release</source><year>2003</year><volume>91</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(03)00240-2</pub-id><pub-id pub-id-type="pmid">12932643</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00276"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>S.</given-names></name>
<name><surname>Su</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Caicun</surname><given-names>Z.</given-names></name>
</person-group><article-title>Integrin-targeted paclitaxel nanoliposomes for tumor therapy</article-title><source>Med. Oncol.</source><year>2011</year><volume>28</volume><fpage>1180</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1007/s12032-010-9621-1</pub-id><pub-id pub-id-type="pmid">20645030</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00276"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>T.M.</given-names></name>
<name><surname>Cullis</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Liposomal drug delivery systems: From concept to clinical applications</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.037</pub-id><pub-id pub-id-type="pmid">23036225</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00276"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bibi</surname><given-names>S.</given-names></name>
<name><surname>Lattmann</surname><given-names>E.</given-names></name>
<name><surname>Mohammed</surname><given-names>A.R.</given-names></name>
<name><surname>Perrie</surname><given-names>Y.</given-names></name>
</person-group><article-title>Trigger release liposome systems: Local and remote controlled delivery?</article-title><source>J. Microencapsul.</source><year>2012</year><volume>29</volume><fpage>262</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.3109/02652048.2011.646330</pub-id><pub-id pub-id-type="pmid">22208705</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00276"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>F.</given-names></name>
<name><surname>Kim</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Thermo-sensitive self-assembly of poly(ethylene imine)/(phenylthio) acetic acid ion pair in surfactant solutions</article-title><source>Drug Deliv.</source><year>2022</year><volume>29</volume><fpage>2245</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2027571</pub-id><pub-id pub-id-type="pmid">35815674</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00276"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yatvin</surname><given-names>M.B.</given-names></name>
<name><surname>Weinstein</surname><given-names>J.N.</given-names></name>
<name><surname>Dennis</surname><given-names>W.H.</given-names></name>
<name><surname>Blumenthal</surname><given-names>R.</given-names></name>
</person-group><article-title>Design of liposomes for enhanced local release of drugs by hyperthermia</article-title><source>Science</source><year>1978</year><volume>202</volume><fpage>1290</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1126/science.364652</pub-id><pub-id pub-id-type="pmid">364652</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00276"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>J.N.</given-names></name>
<name><surname>Magin</surname><given-names>R.L.</given-names></name>
<name><surname>Yatvin</surname><given-names>M.B.</given-names></name>
<name><surname>Zaharko</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumors</article-title><source>Science</source><year>1979</year><volume>204</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1126/science.432641</pub-id><pub-id pub-id-type="pmid">432641</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00276"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yavlovich</surname><given-names>A.</given-names></name>
<name><surname>Smith</surname><given-names>B.</given-names></name>
<name><surname>Gupta</surname><given-names>K.</given-names></name>
<name><surname>Blumenthal</surname><given-names>R.</given-names></name>
<name><surname>Puri</surname><given-names>A.</given-names></name>
</person-group><article-title>Light-sensitive lipid-based nanoparticles for drug delivery: Design principles and future considerations for biological applications</article-title><source>Mol. Membr. Biol.</source><year>2010</year><volume>27</volume><fpage>364</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.3109/09687688.2010.507788</pub-id><pub-id pub-id-type="pmid">20939770</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00276"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bisby</surname><given-names>R.H.</given-names></name>
<name><surname>Mead</surname><given-names>C.</given-names></name>
<name><surname>Morgan</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Photosensitive liposomes as &#x02018;cages&#x02019; for laser-triggered solute delivery: The effect of bilayer cholesterol on kinetics of solute release</article-title><source>FEBS Lett.</source><year>1999</year><volume>463</volume><fpage>165</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(99)01612-9</pub-id><pub-id pub-id-type="pmid">10601660</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00276"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>C.G.</given-names></name>
<name><surname>Thomas</surname><given-names>E.W.</given-names></name>
<name><surname>Sandhu</surname><given-names>S.S.</given-names></name>
<name><surname>Yianni</surname><given-names>Y.P.</given-names></name>
<name><surname>Mitchell</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Light-induced fusion of liposomes with release of trapped marker dye is sensitised by photochromic phospholipid</article-title><source>Biochim. Biophys. Acta</source><year>1987</year><volume>903</volume><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(87)90057-5</pub-id><pub-id pub-id-type="pmid">3663656</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00276"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Matos</surname><given-names>M.B.C.</given-names></name>
<name><surname>Deckers</surname><given-names>R.</given-names></name>
<name><surname>van Elburg</surname><given-names>B.</given-names></name>
<name><surname>Lajoinie</surname><given-names>G.</given-names></name>
<name><surname>de Miranda</surname><given-names>B.S.</given-names></name>
<name><surname>Versluis</surname><given-names>M.</given-names></name>
<name><surname>Schiffelers</surname><given-names>R.</given-names></name>
<name><surname>Kok</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Ultrasound-sensitive liposomes for triggered macromolecular drug delivery: Formulation and in vitro characterization</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>1463</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01463</pub-id><pub-id pub-id-type="pmid">31866867</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00276"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>S.M.</given-names></name>
<name><surname>Chu</surname><given-names>J.H.</given-names></name>
<name><surname>Liu</surname><given-names>X.Z.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>S.Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.M.</given-names></name>
<name><surname>Ju</surname><given-names>R.J.</given-names></name>
<name><surname>Li</surname><given-names>X.T.</given-names></name>
</person-group><article-title>Tumor microenvironmental responsive liposomes simultaneously encapsulating biological and chemotherapeutic drugs for enhancing antitumor efficacy of nsclc</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>6451</fpage><lpage>6468</lpage><pub-id pub-id-type="doi">10.2147/IJN.S258906</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-00276"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidsen</surname><given-names>J.</given-names></name>
<name><surname>Jorgensen</surname><given-names>K.</given-names></name>
<name><surname>Andresen</surname><given-names>T.L.</given-names></name>
<name><surname>Mouritsen</surname><given-names>O.G.</given-names></name>
</person-group><article-title>Secreted phospholipase a(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue</article-title><source>Biochim. Biophys. Acta</source><year>2003</year><volume>1609</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/S0005-2736(02)00659-4</pub-id><pub-id pub-id-type="pmid">12507763</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00276"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarkar</surname><given-names>N.R.</given-names></name>
<name><surname>Rosendahl</surname><given-names>T.</given-names></name>
<name><surname>Krueger</surname><given-names>A.B.</given-names></name>
<name><surname>Banerjee</surname><given-names>A.L.</given-names></name>
<name><surname>Benton</surname><given-names>K.</given-names></name>
<name><surname>Mallik</surname><given-names>S.</given-names></name>
<name><surname>Srivastava</surname><given-names>D.K.</given-names></name>
</person-group><article-title>"Uncorking" of liposomes by matrix metalloproteinase-9</article-title><source>Chem. Commun.</source><year>2005</year><volume>8</volume><fpage>999</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1039/B416827E</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00276"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinn</surname><given-names>J.</given-names></name>
<name><surname>Kwon</surname><given-names>N.</given-names></name>
<name><surname>Lee</surname><given-names>S.A.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
</person-group><article-title>Smart ph-responsive nanomedicines for disease therapy</article-title><source>J. Pharm. Investig.</source><year>2022</year><volume>52</volume><fpage>427</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1007/s40005-022-00573-z</pub-id><pub-id pub-id-type="pmid">35573320</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00276"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Stimulus-responsive nanopreparations for tumor targeting</article-title><source>Integr. Biol.</source><year>2013</year><volume>5</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1039/c2ib20135f</pub-id><pub-id pub-id-type="pmid">22869005</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00276"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>M.S.</given-names></name>
<name><surname>Gomes</surname><given-names>E.R.</given-names></name>
<name><surname>Roque</surname><given-names>M.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Triggered drug release from liposomes: Exploiting the outer and inner tumor environment</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>623760</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.623760</pub-id><pub-id pub-id-type="pmid">33796461</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00276"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>M.</given-names></name>
<name><surname>Lammers</surname><given-names>T.</given-names></name>
<name><surname>Ten Hagen</surname><given-names>T.L.M.</given-names></name>
</person-group><article-title>Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: Towards bypassing epr</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>189</volume><fpage>114503</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2022.114503</pub-id><pub-id pub-id-type="pmid">35998827</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00276"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tak</surname><given-names>W.Y.</given-names></name>
<name><surname>Lin</surname><given-names>S.M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>J.</given-names></name>
<name><surname>Vecchione</surname><given-names>A.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Chen</surname><given-names>M.H.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>R.</given-names></name>
<name><surname>Peng</surname><given-names>C.Y.</given-names></name>
<etal/>
</person-group><article-title>Phase iii heat study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2433</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-00276"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Regenold</surname><given-names>M.</given-names></name>
<name><surname>Bannigan</surname><given-names>P.</given-names></name>
<name><surname>Evans</surname><given-names>J.C.</given-names></name>
<name><surname>Waspe</surname><given-names>A.</given-names></name>
<name><surname>Temple</surname><given-names>M.J.</given-names></name>
<name><surname>Allen</surname><given-names>C.</given-names></name>
</person-group><article-title>Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes</article-title><source>Nanomedicine</source><year>2022</year><volume>40</volume><fpage>102484</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2021.102484</pub-id><pub-id pub-id-type="pmid">34748961</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00276"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
<name><surname>Dalle Ore</surname><given-names>L.C.</given-names></name>
<name><surname>Kwak</surname><given-names>S.</given-names></name>
<name><surname>Kang</surname><given-names>L.</given-names></name>
<name><surname>Kim</surname><given-names>H.K.</given-names></name>
<name><surname>Malmstadt</surname><given-names>N.</given-names></name>
<name><surname>Kim</surname><given-names>S.M.</given-names></name>
<name><surname>Jeon</surname><given-names>T.-J.</given-names></name>
</person-group><article-title>Photoactivable liposomes for controlled delivery: Recent progress and design considerations</article-title><source>Coord. Chem. Rev.</source><year>2024</year><volume>501</volume><fpage>215567</fpage><pub-id pub-id-type="doi">10.1016/j.ccr.2023.215567</pub-id></element-citation></ref><ref id="B58-pharmaceutics-17-00276"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leung</surname><given-names>S.J.</given-names></name>
<name><surname>Romanowski</surname><given-names>M.</given-names></name>
</person-group><article-title>Light-activated content release from liposomes</article-title><source>Theranostics</source><year>2012</year><volume>2</volume><fpage>1020</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.7150/thno.4847</pub-id><pub-id pub-id-type="pmid">23139729</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00276"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery</article-title><source>Nat. Rev. Drug Discov.</source><year>2014</year><volume>13</volume><fpage>813</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/nrd4333</pub-id><pub-id pub-id-type="pmid">25287120</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00276"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yatvin</surname><given-names>M.B.</given-names></name>
<name><surname>Kreutz</surname><given-names>W.</given-names></name>
<name><surname>Horwitz</surname><given-names>B.</given-names></name>
<name><surname>Shinitzky</surname><given-names>M.</given-names></name>
</person-group><article-title>Induced drug release from lipid vesicles in serum by ph-change</article-title><source>Biophys. Struct. Mech.</source><year>1980</year><volume>6</volume><fpage>233</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/BF00537296</pub-id><pub-id pub-id-type="pmid">7417689</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00276"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abri Aghdam</surname><given-names>M.</given-names></name>
<name><surname>Bagheri</surname><given-names>R.</given-names></name>
<name><surname>Mosafer</surname><given-names>J.</given-names></name>
<name><surname>Baradaran</surname><given-names>B.</given-names></name>
<name><surname>Hashemzaei</surname><given-names>M.</given-names></name>
<name><surname>Baghbanzadeh</surname><given-names>A.</given-names></name>
<name><surname>de la Guardia</surname><given-names>M.</given-names></name>
<name><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent advances on thermosensitive and ph-sensitive liposomes employed in controlled release</article-title><source>J. Control. Release</source><year>2019</year><volume>315</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.09.018</pub-id><pub-id pub-id-type="pmid">31647978</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00276"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slepushkin</surname><given-names>V.A.</given-names></name>
<name><surname>Simoes</surname><given-names>S.</given-names></name>
<name><surname>Dazin</surname><given-names>P.</given-names></name>
<name><surname>Newman</surname><given-names>M.S.</given-names></name>
<name><surname>Guo</surname><given-names>L.S.</given-names></name>
<name><surname>Pedroso de Lima</surname><given-names>M.C.</given-names></name>
<name><surname>Duzgunes</surname><given-names>N.</given-names></name>
</person-group><article-title>Sterically stabilized ph-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>2382</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.4.2382</pub-id><pub-id pub-id-type="pmid">8999949</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00276"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>D.C.</given-names></name>
<name><surname>Zignani</surname><given-names>M.</given-names></name>
<name><surname>Leroux</surname><given-names>J.</given-names></name>
</person-group><article-title>Current status of ph-sensitive liposomes in drug delivery</article-title><source>Prog. Lipid Res.</source><year>2000</year><volume>39</volume><fpage>409</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/S0163-7827(00)00011-4</pub-id><pub-id pub-id-type="pmid">11082506</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00276"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mock</surname><given-names>J.N.</given-names></name>
<name><surname>Costyn</surname><given-names>L.J.</given-names></name>
<name><surname>Wilding</surname><given-names>S.L.</given-names></name>
<name><surname>Arnold</surname><given-names>R.D.</given-names></name>
<name><surname>Cummings</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase a2 responsive liposome in prostate cancer</article-title><source>Integr. Biol.</source><year>2013</year><volume>5</volume><fpage>172</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1039/c2ib20108a</pub-id><pub-id pub-id-type="pmid">22890797</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00276"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulkarni</surname><given-names>P.S.</given-names></name>
<name><surname>Haldar</surname><given-names>M.K.</given-names></name>
<name><surname>Nahire</surname><given-names>R.R.</given-names></name>
<name><surname>Katti</surname><given-names>P.</given-names></name>
<name><surname>Ambre</surname><given-names>A.H.</given-names></name>
<name><surname>Muhonen</surname><given-names>W.W.</given-names></name>
<name><surname>Shabb</surname><given-names>J.B.</given-names></name>
<name><surname>Padi</surname><given-names>S.K.</given-names></name>
<name><surname>Singh</surname><given-names>R.K.</given-names></name>
<name><surname>Borowicz</surname><given-names>P.P.</given-names></name>
<etal/>
</person-group><article-title>Mmp-9 responsive peg cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>2390</fpage><lpage>2399</lpage><pub-id pub-id-type="doi">10.1021/mp500108p</pub-id><pub-id pub-id-type="pmid">24827725</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00276"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andresen</surname><given-names>T.L.</given-names></name>
<name><surname>Thompson</surname><given-names>D.H.</given-names></name>
<name><surname>Kaasgaard</surname><given-names>T.</given-names></name>
</person-group><article-title>Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy</article-title><source>Mol. Membr. Biol.</source><year>2010</year><volume>27</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.3109/09687688.2010.515950</pub-id><pub-id pub-id-type="pmid">20939771</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00276"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Nanoparticle-based theranostic agents</article-title><source>Adv. Drug Deliv. Rev.</source><year>2010</year><volume>62</volume><fpage>1064</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2010.07.009</pub-id><pub-id pub-id-type="pmid">20691229</pub-id>
</element-citation></ref><ref id="B68-pharmaceutics-17-00276"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Gnanasammandhan</surname><given-names>M.K.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Optical imaging-guided cancer therapy with fluorescent nanoparticles</article-title><source>J. R. Soc. Interface</source><year>2010</year><volume>7</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1098/rsif.2009.0243</pub-id><pub-id pub-id-type="pmid">19759055</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00276"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liao</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Lv</surname><given-names>R.</given-names></name>
<name><surname>Zhao</surname><given-names>P.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Su</surname><given-names>W.</given-names></name>
<name><surname>Niu</surname><given-names>R.</given-names></name>
<name><surname>Chang</surname><given-names>J.</given-names></name>
</person-group><article-title>Polymeric liposomes-coated superparamagnetic iron oxide nanoparticles as contrast agent for targeted magnetic resonance imaging of cancer cells</article-title><source>Langmuir</source><year>2011</year><volume>27</volume><fpage>3100</fpage><lpage>3105</lpage><pub-id pub-id-type="doi">10.1021/la1050157</pub-id><pub-id pub-id-type="pmid">21341768</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00276"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>J.</given-names></name>
<name><surname>Jaffray</surname><given-names>D.</given-names></name>
<name><surname>Allen</surname><given-names>C.</given-names></name>
</person-group><article-title>Quantitative ct imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model</article-title><source>Mol. Pharm.</source><year>2009</year><volume>6</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1021/mp800234r</pub-id><pub-id pub-id-type="pmid">19298061</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00276"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Man</surname><given-names>F.</given-names></name>
<name><surname>Gawne</surname><given-names>P.J.</given-names></name>
<name><surname>de Rosales</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine</article-title><source>Adv. Drug Deliv. Rev.</source><year>2019</year><volume>143</volume><fpage>134</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2019.05.012</pub-id><pub-id pub-id-type="pmid">31170428</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00276"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Smet</surname><given-names>M.</given-names></name>
<name><surname>Langereis</surname><given-names>S.</given-names></name>
<name><surname>van den Bosch</surname><given-names>S.</given-names></name>
<name><surname>Bitter</surname><given-names>K.</given-names></name>
<name><surname>Hijnen</surname><given-names>N.M.</given-names></name>
<name><surname>Heijman</surname><given-names>E.</given-names></name>
<name><surname>Gr&#x000fc;ll</surname><given-names>H.</given-names></name>
</person-group><article-title>Spect/ct imaging of temperature-sensitive liposomes for mr-image guided drug delivery with high intensity focused ultrasound</article-title><source>J. Control. Release</source><year>2013</year><volume>169</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.04.005</pub-id><pub-id pub-id-type="pmid">23598044</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00276"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L.-Q.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Cui</surname><given-names>X.-W.</given-names></name>
<name><surname>Dietrich</surname><given-names>C.F.</given-names></name>
</person-group><article-title>Ultrasound nanotheranostics in fighting cancer: Advances and prospects</article-title><source>Cancer Lett.</source><year>2020</year><volume>470</volume><fpage>204</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.11.034</pub-id><pub-id pub-id-type="pmid">31790760</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00276"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>N.</given-names></name>
<name><surname>Kalber</surname><given-names>T.L.</given-names></name>
<name><surname>Cooper</surname><given-names>M.S.</given-names></name>
<name><surname>Sunassee</surname><given-names>K.</given-names></name>
<name><surname>Chalker</surname><given-names>S.L.</given-names></name>
<name><surname>Shaw</surname><given-names>K.P.</given-names></name>
<name><surname>Ordidge</surname><given-names>K.L.</given-names></name>
<name><surname>Badar</surname><given-names>A.</given-names></name>
<name><surname>Janes</surname><given-names>S.M.</given-names></name>
<name><surname>Blower</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>Incorporation of paramagnetic, fluorescent and pet/spect contrast agents into liposomes for multimodal imaging</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>1179</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.09.070</pub-id><pub-id pub-id-type="pmid">23131536</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00276"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Ohulchanskyy</surname><given-names>T.Y.</given-names></name>
<name><surname>Yakovliev</surname><given-names>A.</given-names></name>
<name><surname>Zinyuk</surname><given-names>R.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Qu</surname><given-names>J.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Nanoliposomes co-encapsulating ct imaging contrast agent and photosensitizer for enhanced, imaging guided photodynamic therapy of cancer</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>1323</fpage><pub-id pub-id-type="doi">10.7150/thno.31079</pub-id><pub-id pub-id-type="pmid">30867833</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00276"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Askari</surname><given-names>A.</given-names></name>
<name><surname>Tajvar</surname><given-names>S.</given-names></name>
<name><surname>Nikkhah</surname><given-names>M.</given-names></name>
<name><surname>Mohammadi</surname><given-names>S.</given-names></name>
<name><surname>Hosseinkhani</surname><given-names>S.</given-names></name>
</person-group><article-title>Technology Synthesis, characterization and in vitro toxicity evaluation of doxorubicin-loaded magnetoliposomes on mcf-7 breast cancer cell line</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>55</volume><fpage>101447</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101447</pub-id></element-citation></ref><ref id="B77-pharmaceutics-17-00276"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeon</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>W.</given-names></name>
<name><surname>Baek</surname><given-names>S.</given-names></name>
<name><surname>Jung</surname><given-names>H.N.</given-names></name>
<name><surname>Im</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>Development of theranostic dual-layered au-liposome for effective tumor targeting and photothermal therapy</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><elocation-id>262</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-021-01010-3</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-00276"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sonkar</surname><given-names>R.</given-names></name>
<name><surname>Jha</surname><given-names>A.</given-names></name>
<name><surname>Viswanadh</surname><given-names>M.K.</given-names></name>
<name><surname>Burande</surname><given-names>A.S.</given-names></name>
<name><surname>Pawde</surname><given-names>D.M.</given-names></name>
<name><surname>Patel</surname><given-names>K.K.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Koch</surname><given-names>B.</given-names></name>
<name><surname>Muthu</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Gold liposomes for brain-targeted drug delivery: Formulation and brain distribution kinetics</article-title><source>Mater. Sci. Eng. C</source><year>2021</year><volume>120</volume><fpage>111652</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111652</pub-id></element-citation></ref><ref id="B79-pharmaceutics-17-00276"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karpuz</surname><given-names>M.</given-names></name>
<name><surname>Silindir-Gunay</surname><given-names>M.</given-names></name>
<name><surname>Ozer</surname><given-names>A.Y.</given-names></name>
<name><surname>Ozturk</surname><given-names>S.C.</given-names></name>
<name><surname>Yanik</surname><given-names>H.</given-names></name>
<name><surname>Tuncel</surname><given-names>M.</given-names></name>
<name><surname>Aydin</surname><given-names>C.</given-names></name>
<name><surname>Esendagli</surname><given-names>G.</given-names></name>
</person-group><article-title>Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>156</volume><fpage>105576</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105576</pub-id><pub-id pub-id-type="pmid">32987115</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00276"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleusch</surname><given-names>C.</given-names></name>
<name><surname>Hersch</surname><given-names>N.</given-names></name>
<name><surname>Hoffmann</surname><given-names>B.</given-names></name>
<name><surname>Merkel</surname><given-names>R.</given-names></name>
<name><surname>Csiszar</surname><given-names>A.</given-names></name>
</person-group><article-title>Fluorescent lipids: Functional parts of fusogenic liposomes and tools for cell membrane labeling and visualization</article-title><source>Molecules</source><year>2012</year><volume>17</volume><fpage>1055</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.3390/molecules17011055</pub-id><pub-id pub-id-type="pmid">22267193</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00276"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bangham</surname><given-names>A.</given-names></name>
<name><surname>De Gier</surname><given-names>J.</given-names></name>
<name><surname>Greville</surname><given-names>G.</given-names></name>
</person-group><article-title>Osmotic properties and water permeability of phospholipid liquid crystals</article-title><source>Chem. Phys. Lipids</source><year>1967</year><volume>1</volume><fpage>225</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/0009-3084(67)90030-8</pub-id></element-citation></ref><ref id="B82-pharmaceutics-17-00276"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meure</surname><given-names>L.A.</given-names></name>
<name><surname>Foster</surname><given-names>N.R.</given-names></name>
<name><surname>Dehghani</surname><given-names>F.</given-names></name>
</person-group><article-title>Conventional and dense gas techniques for the production of liposomes: A review</article-title><source>AAPS PharmSciTech</source><year>2008</year><volume>9</volume><fpage>798</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1208/s12249-008-9097-x</pub-id><pub-id pub-id-type="pmid">18597175</pub-id>
</element-citation></ref><ref id="B83-pharmaceutics-17-00276"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Justo</surname><given-names>O.R.</given-names></name>
<name><surname>Moraes</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Economical feasibility evaluation of an ethanol injection liposome production plant</article-title><source>Chem. Eng. Technol. Ind. Chem.-Plant Equip.-Process Eng.-Biotechnol.</source><year>2010</year><volume>33</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/ceat.200800502</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-00276"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guimaraes</surname><given-names>D.</given-names></name>
<name><surname>Cavaco-Paulo</surname><given-names>A.</given-names></name>
<name><surname>Nogueira</surname><given-names>E.</given-names></name>
</person-group><article-title>Design of liposomes as drug delivery system for therapeutic applications</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>601</volume><fpage>120571</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120571</pub-id><pub-id pub-id-type="pmid">33812967</pub-id>
</element-citation></ref><ref id="B85-pharmaceutics-17-00276"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zucker</surname><given-names>D.</given-names></name>
<name><surname>Marcus</surname><given-names>D.</given-names></name>
<name><surname>Barenholz</surname><given-names>Y.</given-names></name>
<name><surname>Goldblum</surname><given-names>A.</given-names></name>
</person-group><article-title>Liposome drugs&#x02019; loading efficiency: A working model based on loading conditions and drug&#x02019;s physicochemical properties</article-title><source>J. Control. Release</source><year>2009</year><volume>139</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2009.05.036</pub-id><pub-id pub-id-type="pmid">19508880</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00276"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laouini</surname><given-names>A.</given-names></name>
<name><surname>Jaafar-Maalej</surname><given-names>C.</given-names></name>
<name><surname>Limayem-Blouza</surname><given-names>I.</given-names></name>
<name><surname>Sfar</surname><given-names>S.</given-names></name>
<name><surname>Charcosset</surname><given-names>C.</given-names></name>
<name><surname>Fessi</surname><given-names>H.</given-names></name>
</person-group><article-title>Biotechnology Preparation, characterization and applications of liposomes: State of the art</article-title><source>J. Colloid Sci. Biotechnol.</source><year>2012</year><volume>1</volume><fpage>147</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1166/jcsb.2012.1020</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-00276"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danaei</surname><given-names>M.</given-names></name>
<name><surname>Dehghankhold</surname><given-names>M.</given-names></name>
<name><surname>Ataei</surname><given-names>S.</given-names></name>
<name><surname>Hasanzadeh Davarani</surname><given-names>F.</given-names></name>
<name><surname>Javanmard</surname><given-names>R.</given-names></name>
<name><surname>Dokhani</surname><given-names>A.</given-names></name>
<name><surname>Khorasani</surname><given-names>S.</given-names></name>
<name><surname>Mozafari</surname><given-names>M.</given-names></name>
</person-group><article-title>Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics10020057</pub-id><pub-id pub-id-type="pmid">29783687</pub-id>
</element-citation></ref><ref id="B88-pharmaceutics-17-00276"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nemeth</surname><given-names>Z.</given-names></name>
<name><surname>Csoka</surname><given-names>I.</given-names></name>
<name><surname>Semnani Jazani</surname><given-names>R.</given-names></name>
<name><surname>Sipos</surname><given-names>B.</given-names></name>
<name><surname>Haspel</surname><given-names>H.</given-names></name>
<name><surname>Kozma</surname><given-names>G.</given-names></name>
<name><surname>Konya</surname><given-names>Z.</given-names></name>
<name><surname>Dobo</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Quality by design-driven zeta potential optimisation study of liposomes with charge imparting membrane additives</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1798</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14091798</pub-id><pub-id pub-id-type="pmid">36145546</pub-id>
</element-citation></ref><ref id="B89-pharmaceutics-17-00276"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmood</surname><given-names>S.</given-names></name>
<name><surname>Mandal</surname><given-names>U.K.</given-names></name>
<name><surname>Chatterjee</surname><given-names>B.</given-names></name>
<name><surname>Taher</surname><given-names>M.</given-names></name>
</person-group><article-title>Advanced characterizations of nanoparticles for drug delivery: Investigating their properties through the techniques used in their evaluations</article-title><source>Nanotechnol. Rev.</source><year>2017</year><volume>6</volume><fpage>355</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1515/ntrev-2016-0050</pub-id></element-citation></ref><ref id="B90-pharmaceutics-17-00276"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakonyi</surname><given-names>M.</given-names></name>
<name><surname>Berk&#x000f3;</surname><given-names>S.</given-names></name>
<name><surname>Budai-Sz&#x00171;cs</surname><given-names>M.</given-names></name>
<name><surname>Kov&#x000e1;cs</surname><given-names>A.</given-names></name>
<name><surname>Cs&#x000e1;nyi</surname><given-names>E.</given-names></name>
</person-group><article-title>Calorimetry Dsc for evaluating the encapsulation efficiency of lidocaine-loaded liposomes compared to the ultracentrifugation method</article-title><source>J. Therm. Anal. Calorim.</source><year>2017</year><volume>130</volume><fpage>1619</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1007/s10973-017-6394-1</pub-id></element-citation></ref><ref id="B91-pharmaceutics-17-00276"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dash</surname><given-names>S.</given-names></name>
<name><surname>Murthy</surname><given-names>P.N.</given-names></name>
<name><surname>Nath</surname><given-names>L.</given-names></name>
<name><surname>Chowdhury</surname><given-names>P.</given-names></name>
</person-group><article-title>Kinetic modeling on drug release from controlled drug delivery systems</article-title><source>Acta Pol. Pharm.</source><year>2010</year><volume>67</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">20524422</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00276"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Adepoju</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>S.</given-names></name>
<name><surname>Perez Tetuan</surname><given-names>J.</given-names></name>
<name><surname>Williams</surname><given-names>M.</given-names></name>
<name><surname>Abdelmessih</surname><given-names>R.G.</given-names></name>
<name><surname>Auguste</surname><given-names>D.T.</given-names></name>
<name><surname>Hung</surname><given-names>F.R.</given-names></name>
</person-group><article-title>Effects of lipid headgroups on the mechanical properties and in vitro cellular internalization of liposomes</article-title><source>Langmuir</source><year>2025</year><volume>41</volume><fpage>2600</fpage><lpage>2618</lpage><pub-id pub-id-type="doi">10.1021/acs.langmuir.4c04363</pub-id><pub-id pub-id-type="pmid">39834158</pub-id>
</element-citation></ref><ref id="B93-pharmaceutics-17-00276"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakai-Kato</surname><given-names>K.</given-names></name>
<name><surname>Yoshida</surname><given-names>K.</given-names></name>
<name><surname>Izutsu</surname><given-names>K.I.</given-names></name>
</person-group><article-title>Effect of surface charge on the size-dependent cellular internalization of liposomes</article-title><source>Chem. Phys. Lipids</source><year>2019</year><volume>224</volume><fpage>104726</fpage><pub-id pub-id-type="doi">10.1016/j.chemphyslip.2019.01.004</pub-id><pub-id pub-id-type="pmid">30660745</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00276"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>M.M.</given-names></name>
<name><surname>Wilson</surname><given-names>W.R.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Ph-sensitive pegylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>516</volume><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.11.041</pub-id><pub-id pub-id-type="pmid">27871834</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00276"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Xue</surname><given-names>L.</given-names></name>
<name><surname>Su</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
</person-group><article-title>Cellular vehicles based on neutrophils enable targeting of atherosclerosis</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>3109</fpage><lpage>3120</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00342</pub-id><pub-id pub-id-type="pmid">31082253</pub-id>
</element-citation></ref><ref id="B96-pharmaceutics-17-00276"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mudhakir</surname><given-names>D.</given-names></name>
<name><surname>Akita</surname><given-names>H.</given-names></name>
<name><surname>Harashima</surname><given-names>H.</given-names></name>
</person-group><article-title>Topology of octaarginines (r8) or irq ligand on liposomes affects the contribution of macropinocytosis- and caveolae-mediated cellular uptake</article-title><source>React. Funct. Polym.</source><year>2011</year><volume>71</volume><fpage>340</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.reactfunctpolym.2010.11.013</pub-id></element-citation></ref><ref id="B97-pharmaceutics-17-00276"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakai-Kato</surname><given-names>K.</given-names></name>
<name><surname>Yoshida</surname><given-names>K.</given-names></name>
<name><surname>Takechi-Haraya</surname><given-names>Y.</given-names></name>
<name><surname>Izutsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Physicochemical characterization of liposomes that mimic the lipid composition of exosomes for effective intracellular trafficking</article-title><source>Langmuir</source><year>2020</year><volume>36</volume><fpage>12735</fpage><lpage>12744</lpage><pub-id pub-id-type="doi">10.1021/acs.langmuir.0c02491</pub-id><pub-id pub-id-type="pmid">33054220</pub-id>
</element-citation></ref><ref id="B98-pharmaceutics-17-00276"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashby</surname><given-names>G.</given-names></name>
<name><surname>Keng</surname><given-names>K.E.</given-names></name>
<name><surname>Hayden</surname><given-names>C.C.</given-names></name>
<name><surname>Gollapudi</surname><given-names>S.</given-names></name>
<name><surname>Houser</surname><given-names>J.R.</given-names></name>
<name><surname>Jamal</surname><given-names>S.</given-names></name>
<name><surname>Stachowiak</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Selective endocytic uptake of targeted liposomes occurs within a narrow range of liposome diameters</article-title><source>ACS Appl. Mater. Inter.</source><year>2023</year><volume>15</volume><fpage>49988</fpage><lpage>50001</lpage><pub-id pub-id-type="doi">10.1021/acsami.3c09399</pub-id></element-citation></ref><ref id="B99-pharmaceutics-17-00276"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Y.T.</given-names></name>
<name><surname>Hong</surname><given-names>S.L.</given-names></name>
<name><surname>Xie</surname><given-names>R.</given-names></name>
<name><surname>Huang</surname><given-names>R.B.</given-names></name>
<name><surname>Lei</surname><given-names>R.X.</given-names></name>
<name><surname>Cheng</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>D.E.</given-names></name>
<name><surname>Du</surname><given-names>Y.F.</given-names></name>
<name><surname>Nycholat</surname><given-names>C.M.</given-names></name>
<name><surname>Paulson</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Mechanistic investigation and multiplexing of liposome-assisted metabolic glycan labeling</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>3592</fpage><lpage>3602</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b10990</pub-id><pub-id pub-id-type="pmid">29446631</pub-id>
</element-citation></ref><ref id="B100-pharmaceutics-17-00276"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>Y.N.</given-names></name>
<name><surname>Zhang</surname><given-names>L.H.</given-names></name>
<name><surname>Song</surname><given-names>C.X.</given-names></name>
</person-group><article-title>Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using lhrh analogs modified with pegylated liposomes</article-title><source>Int. J. Nanomed.</source><year>2010</year><volume>5</volume><fpage>697</fpage><lpage>705</lpage></element-citation></ref><ref id="B101-pharmaceutics-17-00276"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirose</surname><given-names>M.</given-names></name>
<name><surname>Ueno</surname><given-names>T.</given-names></name>
<name><surname>Nagumo</surname><given-names>H.</given-names></name>
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Sakai-Kato</surname><given-names>K.</given-names></name>
</person-group><article-title>Enhancing the endocytosis of phosphatidylserine-containing liposomes through tim4 by modulation of membrane fluidity</article-title><source>Mol. Pharm.</source><year>2022</year><volume>19</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.1c00645</pub-id><pub-id pub-id-type="pmid">34913345</pub-id>
</element-citation></ref><ref id="B102-pharmaceutics-17-00276"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takechi-Haraya</surname><given-names>Y.</given-names></name>
<name><surname>Goda</surname><given-names>Y.</given-names></name>
<name><surname>Sakai-Kato</surname><given-names>K.</given-names></name>
</person-group><article-title>Control of liposomal penetration into three-dimensional multicellular tumor spheroids by modulating liposomal membrane rigidity</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>2158</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00051</pub-id><pub-id pub-id-type="pmid">28410440</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00276"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Working</surname><given-names>P.K.</given-names></name>
<name><surname>Newman</surname><given-names>M.S.</given-names></name>
<name><surname>Huang</surname><given-names>S.K.</given-names></name>
<name><surname>Mayhew</surname><given-names>E.</given-names></name>
<name><surname>Vaage</surname><given-names>J.</given-names></name>
<name><surname>Lasic</surname><given-names>D.D.</given-names></name>
</person-group><article-title>Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth&#x000ae; liposomes (doxil&#x000ae;)</article-title><source>J. Liposome Res.</source><year>1994</year><volume>4</volume><fpage>667</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.3109/08982109409037065</pub-id></element-citation></ref><ref id="B104-pharmaceutics-17-00276"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gabizon</surname><given-names>A.</given-names></name>
<name><surname>Catane</surname><given-names>R.</given-names></name>
<name><surname>Uziely</surname><given-names>B.</given-names></name>
<name><surname>Kaufman</surname><given-names>B.</given-names></name>
<name><surname>Safra</surname><given-names>T.</given-names></name>
<name><surname>Cohen</surname><given-names>R.</given-names></name>
<name><surname>Martin</surname><given-names>F.</given-names></name>
<name><surname>Huang</surname><given-names>A.</given-names></name>
<name><surname>Barenholz</surname><given-names>Y.</given-names></name>
</person-group><article-title>Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes</article-title><source>Cancer Res.</source><year>1994</year><volume>54</volume><fpage>987</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">8313389</pub-id>
</element-citation></ref><ref id="B105-pharmaceutics-17-00276"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soloman</surname><given-names>R.</given-names></name>
<name><surname>Gabizon</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin</article-title><source>Clin. Lymphoma Myeloma</source><year>2008</year><volume>8</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.3816/CLM.2008.n.001</pub-id><pub-id pub-id-type="pmid">18501085</pub-id>
</element-citation></ref><ref id="B106-pharmaceutics-17-00276"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szebeni</surname><given-names>J.</given-names></name>
<name><surname>Baranyi</surname><given-names>L.</given-names></name>
<name><surname>Savay</surname><given-names>S.</given-names></name>
<name><surname>Milosevits</surname><given-names>J.</given-names></name>
<name><surname>Bunger</surname><given-names>R.</given-names></name>
<name><surname>Laverman</surname><given-names>P.</given-names></name>
<name><surname>Metselaar</surname><given-names>J.M.</given-names></name>
<name><surname>Storm</surname><given-names>G.</given-names></name>
<name><surname>Chanan-Khan</surname><given-names>A.</given-names></name>
<name><surname>Liebes</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Role of complement activation in hypersensitivity reactions to doxil and hynic peg liposomes: Experimental and clinical studies</article-title><source>J. Liposome Res.</source><year>2002</year><volume>12</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1081/LPR-120004790</pub-id><pub-id pub-id-type="pmid">12604051</pub-id>
</element-citation></ref><ref id="B107-pharmaceutics-17-00276"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gill</surname><given-names>P.S.</given-names></name>
<name><surname>Espina</surname><given-names>B.M.</given-names></name>
<name><surname>Muggia</surname><given-names>F.</given-names></name>
<name><surname>Cabriales</surname><given-names>S.</given-names></name>
<name><surname>Tulpule</surname><given-names>A.</given-names></name>
<name><surname>Esplin</surname><given-names>J.A.</given-names></name>
<name><surname>Liebman</surname><given-names>H.A.</given-names></name>
<name><surname>Forssen</surname><given-names>E.</given-names></name>
<name><surname>Ross</surname><given-names>M.E.</given-names></name>
<name><surname>Levine</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Phase i/ii clinical and pharmacokinetic evaluation of liposomal daunorubicin</article-title><source>J. Clin. Oncol.</source><year>1995</year><volume>13</volume><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1200/JCO.1995.13.4.996</pub-id><pub-id pub-id-type="pmid">7707129</pub-id>
</element-citation></ref><ref id="B108-pharmaceutics-17-00276"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petre</surname><given-names>C.E.</given-names></name>
<name><surname>Dittmer</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Liposomal daunorubicin as treatment for kaposi&#x02019;s sarcoma</article-title><source>Int. J. Nanomed.</source><year>2007</year><volume>2</volume><fpage>277</fpage><lpage>288</lpage></element-citation></ref><ref id="B109-pharmaceutics-17-00276"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batist</surname><given-names>G.</given-names></name>
<name><surname>Barton</surname><given-names>J.</given-names></name>
<name><surname>Chaikin</surname><given-names>P.</given-names></name>
<name><surname>Swenson</surname><given-names>C.</given-names></name>
<name><surname>Welles</surname><given-names>L.</given-names></name>
</person-group><article-title>Myocet (liposome-encapsulated doxorubicin citrate): A new approach in breast cancer therapy</article-title><source>Expert. Opin. Pharmacother.</source><year>2002</year><volume>3</volume><fpage>1739</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1517/14656566.3.12.1739</pub-id><pub-id pub-id-type="pmid">12472371</pub-id>
</element-citation></ref><ref id="B110-pharmaceutics-17-00276"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nardin</surname><given-names>A.</given-names></name>
<name><surname>Lefebvre</surname><given-names>M.L.</given-names></name>
<name><surname>Labroquere</surname><given-names>K.</given-names></name>
<name><surname>Faure</surname><given-names>O.</given-names></name>
<name><surname>Abastado</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma</article-title><source>Curr. Cancer Drug Targets</source><year>2006</year><volume>6</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.2174/156800906776056473</pub-id><pub-id pub-id-type="pmid">16529542</pub-id>
</element-citation></ref><ref id="B111-pharmaceutics-17-00276"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>J.A.</given-names></name>
<name><surname>Deitcher</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Marqibo(r) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine</article-title><source>Cancer Chemother. Pharmacol.</source><year>2013</year><volume>71</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1007/s00280-012-2042-4</pub-id><pub-id pub-id-type="pmid">23212117</pub-id>
</element-citation></ref><ref id="B112-pharmaceutics-17-00276"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bailly</surname><given-names>C.</given-names></name>
</person-group><article-title>Irinotecan: 25 years of cancer treatment</article-title><source>Pharmacol. Res.</source><year>2019</year><volume>148</volume><fpage>104398</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104398</pub-id><pub-id pub-id-type="pmid">31415916</pub-id>
</element-citation></ref><ref id="B113-pharmaceutics-17-00276"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Milano</surname><given-names>G.</given-names></name>
<name><surname>Innocenti</surname><given-names>F.</given-names></name>
<name><surname>Minami</surname><given-names>H.</given-names></name>
</person-group><article-title>Liposomal irinotecan (onivyde): Exemplifying the benefits of nanotherapeutic drugs</article-title><source>Cancer Sci.</source><year>2022</year><volume>113</volume><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1111/cas.15377</pub-id><pub-id pub-id-type="pmid">35445479</pub-id>
</element-citation></ref><ref id="B114-pharmaceutics-17-00276"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfayez</surname><given-names>M.</given-names></name>
<name><surname>Kantarjian</surname><given-names>H.</given-names></name>
<name><surname>Kadia</surname><given-names>T.</given-names></name>
<name><surname>Ravandi-Kashani</surname><given-names>F.</given-names></name>
<name><surname>Daver</surname><given-names>N.</given-names></name>
</person-group><article-title>Cpx-351 (vyxeos) in aml</article-title><source>Leuk. Lymphoma</source><year>2020</year><volume>61</volume><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1080/10428194.2019.1660970</pub-id><pub-id pub-id-type="pmid">31547736</pub-id>
</element-citation></ref><ref id="B115-pharmaceutics-17-00276"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lancet</surname><given-names>J.E.</given-names></name>
<name><surname>Uy</surname><given-names>G.L.</given-names></name>
<name><surname>Cortes</surname><given-names>J.E.</given-names></name>
<name><surname>Newell</surname><given-names>L.F.</given-names></name>
<name><surname>Lin</surname><given-names>T.L.</given-names></name>
<name><surname>Ritchie</surname><given-names>E.K.</given-names></name>
<name><surname>Stuart</surname><given-names>R.K.</given-names></name>
<name><surname>Strickland</surname><given-names>S.A.</given-names></name>
<name><surname>Hogge</surname><given-names>D.</given-names></name>
<name><surname>Solomon</surname><given-names>S.R.</given-names></name>
<etal/>
</person-group><article-title>Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>2684</fpage><lpage>2692</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.77.6112</pub-id><pub-id pub-id-type="pmid">30024784</pub-id>
</element-citation></ref><ref id="B116-pharmaceutics-17-00276"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Angst</surname><given-names>M.S.</given-names></name>
<name><surname>Drover</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Pharmacology of drugs formulated with depofoam: A sustained release drug delivery system for parenteral administration using multivesicular liposome technology</article-title><source>Clin. Pharmacokinet.</source><year>2006</year><volume>45</volume><fpage>1153</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.2165/00003088-200645120-00002</pub-id><pub-id pub-id-type="pmid">17112293</pub-id>
</element-citation></ref><ref id="B117-pharmaceutics-17-00276"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>M.</given-names></name>
<name><surname>Abuwatfa</surname><given-names>W.H.</given-names></name>
<name><surname>Awad</surname><given-names>N.S.</given-names></name>
<name><surname>Sabouni</surname><given-names>R.</given-names></name>
<name><surname>Husseini</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: A review</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>254</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14020254</pub-id><pub-id pub-id-type="pmid">35213987</pub-id>
</element-citation></ref><ref id="B118-pharmaceutics-17-00276"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>I.</given-names></name>
<name><surname>Koster</surname><given-names>K.L.</given-names></name>
<name><surname>Holer</surname><given-names>L.</given-names></name>
<name><surname>Haefliger</surname><given-names>S.</given-names></name>
<name><surname>Rabaglio</surname><given-names>M.</given-names></name>
<name><surname>Bastian</surname><given-names>S.</given-names></name>
<name><surname>Schwitter</surname><given-names>M.</given-names></name>
<name><surname>Eckhardt</surname><given-names>K.</given-names></name>
<name><surname>Hayoz</surname><given-names>S.</given-names></name>
<name><surname>Mc Laughlin</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>Tld-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase i trial (sakk 65/16)</article-title><source>Eur. J. Cancer</source><year>2024</year><volume>201</volume><fpage>113588</fpage><pub-id pub-id-type="doi">10.1016/j.ejca.2024.113588</pub-id><pub-id pub-id-type="pmid">38377773</pub-id>
</element-citation></ref><ref id="B119-pharmaceutics-17-00276"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>A.</given-names></name>
<name><surname>Pommier</surname><given-names>Y.</given-names></name>
</person-group><article-title>Targeting topoisomerase i in the era of precision medicine</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>6581</fpage><lpage>6589</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1089</pub-id></element-citation></ref><ref id="B120-pharmaceutics-17-00276"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimoyama</surname><given-names>S.</given-names></name>
<name><surname>Okada</surname><given-names>K.</given-names></name>
<name><surname>Kimura</surname><given-names>T.</given-names></name>
<name><surname>Morohashi</surname><given-names>Y.</given-names></name>
<name><surname>Nakayama</surname><given-names>S.</given-names></name>
<name><surname>Kemmochi</surname><given-names>S.</given-names></name>
<name><surname>Makita-Suzuki</surname><given-names>K.</given-names></name>
<name><surname>Matulonis</surname><given-names>U.A.</given-names></name>
<name><surname>Mori</surname><given-names>M.</given-names></name>
</person-group><article-title>Ff-10850, a novel liposomal topotecan achieves superior antitumor activity via macrophage- and ammonia-mediated payload release in the tumor microenvironment</article-title><source>Mol. Cancer Ther.</source><year>2023</year><volume>22</volume><fpage>1454</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-23-0099</pub-id><pub-id pub-id-type="pmid">37683276</pub-id>
</element-citation></ref><ref id="B121-pharmaceutics-17-00276"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>D.C.</given-names></name>
<name><surname>Noble</surname><given-names>C.O.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Hong</surname><given-names>K.</given-names></name>
<name><surname>Park</surname><given-names>J.W.</given-names></name>
<name><surname>Kirpotin</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>3271</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4007</pub-id><pub-id pub-id-type="pmid">16540680</pub-id>
</element-citation></ref><ref id="B122-pharmaceutics-17-00276"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Przespolewski</surname><given-names>A.</given-names></name>
<name><surname>Goldberg</surname><given-names>A.D.</given-names></name>
<name><surname>Talati</surname><given-names>C.</given-names></name>
<name><surname>Fazal</surname><given-names>S.</given-names></name>
<name><surname>Vachhani</surname><given-names>P.</given-names></name>
<name><surname>Sanikommu</surname><given-names>S.R.</given-names></name>
<name><surname>Thota</surname><given-names>S.</given-names></name>
<name><surname>Waksal</surname><given-names>J.</given-names></name>
<name><surname>Ball</surname><given-names>B.</given-names></name>
<name><surname>Famulare</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Safety and efficacy of cpx-351 in younger patients (&#x0003c;60 years old) with secondary acute myeloid leukemia</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>1489</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1182/blood.2022016678</pub-id><pub-id pub-id-type="pmid">36493344</pub-id>
</element-citation></ref><ref id="B123-pharmaceutics-17-00276"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tahaghoghi-Hajghorbani</surname><given-names>S.</given-names></name>
<name><surname>Yazdani</surname><given-names>M.</given-names></name>
<name><surname>Nikpoor</surname><given-names>A.R.</given-names></name>
<name><surname>Hatamipour</surname><given-names>M.</given-names></name>
<name><surname>Ajami</surname><given-names>A.</given-names></name>
<name><surname>Jaafari</surname><given-names>M.R.</given-names></name>
<name><surname>Badiee</surname><given-names>A.</given-names></name>
<name><surname>Rafiei</surname><given-names>A.</given-names></name>
</person-group><article-title>Targeting the tumor microenvironment by liposomal epacadostat in combination with liposomal gp100 vaccine</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>5802</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-31007-x</pub-id><pub-id pub-id-type="pmid">37037839</pub-id>
</element-citation></ref><ref id="B124-pharmaceutics-17-00276"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doonan</surname><given-names>B.</given-names></name>
<name><surname>Shaw</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>J.-H.</given-names></name>
<name><surname>Manso</surname><given-names>E.</given-names></name>
<name><surname>Mendez-Gomez</surname><given-names>H.</given-names></name>
<name><surname>Roemeling</surname><given-names>C.</given-names></name>
<name><surname>Mitchell</surname><given-names>D.</given-names></name>
<name><surname>Sayour</surname><given-names>E.</given-names></name>
</person-group><article-title>772 novel rna-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-pd-1 antibody therapy</article-title><source>J. ImmunoTherapy Cancer</source><year>2023</year><volume>11</volume><fpage>867</fpage><lpage>869</lpage></element-citation></ref><ref id="B125-pharmaceutics-17-00276"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>G.</given-names></name>
<name><surname>Choi</surname><given-names>Y.</given-names></name>
<name><surname>Hong</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Chae</surname><given-names>J.</given-names></name>
<name><surname>Ahn</surname><given-names>S.</given-names></name>
<name><surname>Ha</surname><given-names>H.</given-names></name>
<name><surname>Jeong</surname><given-names>E.</given-names></name>
<name><surname>Lee</surname><given-names>H.-Y.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
</person-group><article-title>All-rounder liposomes in cancer immunotherapy: Strategies and design applications of engineered liposomal nanomaterials</article-title><source>BioChip J.</source><year>2024</year><volume>18</volume><fpage>211</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/s13206-024-00147-1</pub-id></element-citation></ref><ref id="B126-pharmaceutics-17-00276"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Modulating mdscs by hf1k16: A mono-therapy phase ia study examining safety and preliminary efficacy in patients with refractory and metastatic cancer</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><issue>(Suppl. S16)</issue><fpage>e14040</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.e14040</pub-id></element-citation></ref><ref id="B127-pharmaceutics-17-00276"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>R.</given-names></name>
<name><surname>Salave</surname><given-names>S.</given-names></name>
<name><surname>Rana</surname><given-names>D.</given-names></name>
<name><surname>Karunakaran</surname><given-names>B.</given-names></name>
<name><surname>Butreddy</surname><given-names>A.</given-names></name>
<name><surname>Benival</surname><given-names>D.</given-names></name>
<name><surname>Kommineni</surname><given-names>N.</given-names></name>
</person-group><article-title>Versatility of liposomes for antisense oligonucleotide delivery: A special focus on various therapeutic areas</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1435</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15051435</pub-id><pub-id pub-id-type="pmid">37242677</pub-id>
</element-citation></ref><ref id="B128-pharmaceutics-17-00276"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaloni</surname><given-names>D.</given-names></name>
<name><surname>Diepstraten</surname><given-names>S.T.</given-names></name>
<name><surname>Strasser</surname><given-names>A.</given-names></name>
<name><surname>Kelly</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Bcl-2 protein family: Attractive targets for cancer therapy</article-title><source>Apoptosis Int. J. Program. Cell Death</source><year>2023</year><volume>28</volume><fpage>20</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s10495-022-01780-7</pub-id></element-citation></ref><ref id="B129-pharmaceutics-17-00276"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gagliardi</surname><given-names>M.</given-names></name>
<name><surname>Ashizawa</surname><given-names>A.T.</given-names></name>
</person-group><article-title>Making sense of antisense oligonucleotide therapeutics targeting bcl-2</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>97</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14010097</pub-id><pub-id pub-id-type="pmid">35056993</pub-id>
</element-citation></ref><ref id="B130-pharmaceutics-17-00276"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Komori</surname><given-names>T.</given-names></name>
<name><surname>Yoshino</surname><given-names>Y.</given-names></name>
<name><surname>Ioroi</surname><given-names>T.</given-names></name>
<name><surname>Kitahashi</surname><given-names>T.</given-names></name>
<name><surname>Kitahara</surname><given-names>H.</given-names></name>
<name><surname>Ono</surname><given-names>K.</given-names></name>
<name><surname>Higuchi</surname><given-names>T.</given-names></name>
<name><surname>Sakabe</surname><given-names>M.</given-names></name>
<name><surname>Kori</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A liposomal gemcitabine, ff-10832, improves plasma stability, tumor targeting, and antitumor efficacy of gemcitabine in pancreatic cancer xenograft models</article-title><source>Pharm. Res.</source><year>2021</year><volume>38</volume><fpage>1093</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1007/s11095-021-03045-5</pub-id><pub-id pub-id-type="pmid">33961188</pub-id>
</element-citation></ref><ref id="B131-pharmaceutics-17-00276"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borazanci</surname><given-names>E.H.</given-names></name>
<name><surname>Janku</surname><given-names>F.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.P.</given-names></name>
<name><surname>Thomas</surname><given-names>J.S.</given-names></name>
<name><surname>Sen</surname><given-names>S.</given-names></name>
<name><surname>Fu</surname><given-names>S.</given-names></name>
<name><surname>Wheeler</surname><given-names>C.A.</given-names></name>
<name><surname>Wages</surname><given-names>D.S.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Shimoyama</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (ff-10832) in patients with advanced solid tumors</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><issue>(Suppl. S16)</issue><fpage>3097</fpage><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.3097</pub-id></element-citation></ref><ref id="B132-pharmaceutics-17-00276"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Langer</surname><given-names>C.J.</given-names></name>
<name><surname>Curti</surname><given-names>B.D.</given-names></name>
<name><surname>Farber</surname><given-names>C.M.</given-names></name>
<name><surname>Wheeler</surname><given-names>C.A.</given-names></name>
<name><surname>Wages</surname><given-names>D.S.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Shimoyama</surname><given-names>S.</given-names></name>
<name><surname>Mori</surname><given-names>M.</given-names></name>
<name><surname>Yamada</surname><given-names>N.</given-names></name>
<name><surname>Subach</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group><article-title>A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (ff-10832) in combination with pembrolizumab in patients with advanced solid tumors</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><issue>(Suppl. S16)</issue><fpage>2615</fpage><pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.2615</pub-id></element-citation></ref><ref id="B133-pharmaceutics-17-00276"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>W.T.</given-names></name>
<name><surname>Goins</surname><given-names>B.</given-names></name>
<name><surname>Bao</surname><given-names>A.</given-names></name>
<name><surname>Vargas</surname><given-names>D.</given-names></name>
<name><surname>Guttierez</surname><given-names>J.E.</given-names></name>
<name><surname>Trevino</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>J.R.</given-names></name>
<name><surname>Henry</surname><given-names>J.</given-names></name>
<name><surname>Zuniga</surname><given-names>R.</given-names></name>
<name><surname>Vecil</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma</article-title><source>Neuro-Oncology</source><year>2012</year><volume>14</volume><fpage>416</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos060</pub-id><pub-id pub-id-type="pmid">22427110</pub-id>
</element-citation></ref><ref id="B134-pharmaceutics-17-00276"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LaFrance</surname><given-names>N.</given-names></name>
<name><surname>Brenner</surname><given-names>A.</given-names></name>
<name><surname>Patel</surname><given-names>T.</given-names></name>
<name><surname>Youssef</surname><given-names>M.</given-names></name>
<name><surname>Bao</surname><given-names>A.</given-names></name>
<name><surname>Phillips</surname><given-names>W.</given-names></name>
<name><surname>Hedrick</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>M.</given-names></name>
<name><surname>Weinberg</surname><given-names>J.</given-names></name>
<name><surname>Floyd</surname><given-names>J.</given-names></name>
</person-group><article-title>Safety and feasibility results from a phase 1/2 clinical trial of 186rnl (rhenium-186 nanoliposome) (186re) obisbemeda in recurrent glioma: The respect-gbm trial</article-title><source>J. Nucl. Med.</source><year>2023</year><volume>64</volume><issue>(Suppl. S1)</issue><fpage>P988</fpage></element-citation></ref><ref id="B135-pharmaceutics-17-00276"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dadpour</surname><given-names>S.</given-names></name>
<name><surname>Mehrabian</surname><given-names>A.</given-names></name>
<name><surname>Arabsalmani</surname><given-names>M.</given-names></name>
<name><surname>Mirhadi</surname><given-names>E.</given-names></name>
<name><surname>Askarizadeh</surname><given-names>A.</given-names></name>
<name><surname>Mashreghi</surname><given-names>M.</given-names></name>
<name><surname>Jaafari</surname><given-names>M.R.</given-names></name>
</person-group><article-title>The role of size in pegylated liposomal doxorubicin biodistribution and anti-tumour activity</article-title><source>IET Nanobiotechnol.</source><year>2022</year><volume>16</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1049/nbt2.12094</pub-id><pub-id pub-id-type="pmid">35983586</pub-id>
</element-citation></ref><ref id="B136-pharmaceutics-17-00276"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dou</surname><given-names>Y.</given-names></name>
<name><surname>Hynynen</surname><given-names>K.</given-names></name>
<name><surname>Allen</surname><given-names>C.</given-names></name>
</person-group><article-title>To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes</article-title><source>J. Control. Release</source><year>2017</year><volume>249</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.01.025</pub-id><pub-id pub-id-type="pmid">28122204</pub-id>
</element-citation></ref><ref id="B137-pharmaceutics-17-00276"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>A.</given-names></name>
<name><surname>Xie</surname><given-names>F.</given-names></name>
<name><surname>Shi</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Long</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Sustained drug release from liposomes for the remodeling of systemic immune homeostasis and the tumor microenvironment</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>829391</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.829391</pub-id><pub-id pub-id-type="pmid">35493504</pub-id>
</element-citation></ref><ref id="B138-pharmaceutics-17-00276"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dotan</surname><given-names>E.</given-names></name>
<name><surname>Catalano</surname><given-names>P.</given-names></name>
<name><surname>Lenchik</surname><given-names>L.</given-names></name>
<name><surname>Boutin</surname><given-names>R.</given-names></name>
<name><surname>Yao</surname><given-names>X.</given-names></name>
<name><surname>Marques</surname><given-names>H.S.</given-names></name>
<name><surname>Ioffe</surname><given-names>D.</given-names></name>
<name><surname>Zhen</surname><given-names>D.B.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Wagner</surname><given-names>L.I.</given-names></name>
<etal/>
</person-group><article-title>The giant trial (ecog-acrin ea2186) methods paper: A randomized phase ii study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na&#x000ef;ve metastatic pancreatic cancer-defining a new treatment option for older vulnerable patients</article-title><source>J. Geriatr. Oncol.</source><year>2023</year><volume>14</volume><fpage>101474</fpage><pub-id pub-id-type="doi">10.1016/j.jgo.2023.101474</pub-id><pub-id pub-id-type="pmid">36963200</pub-id>
</element-citation></ref><ref id="B139-pharmaceutics-17-00276"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>DesJardins</surname><given-names>C.</given-names></name>
<name><surname>Saxton</surname><given-names>P.</given-names></name>
<name><surname>Lai</surname><given-names>G.</given-names></name>
<name><surname>Schuck</surname><given-names>E.</given-names></name>
<name><surname>Wong</surname><given-names>Y.N.</given-names></name>
</person-group><article-title>Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (e7389) in mice</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>443</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.01.010</pub-id><pub-id pub-id-type="pmid">23313921</pub-id>
</element-citation></ref><ref id="B140-pharmaceutics-17-00276"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masuda</surname><given-names>N.</given-names></name>
<name><surname>Ono</surname><given-names>M.</given-names></name>
<name><surname>Mukohara</surname><given-names>T.</given-names></name>
<name><surname>Yasojima</surname><given-names>H.</given-names></name>
<name><surname>Shimoi</surname><given-names>T.</given-names></name>
<name><surname>Kobayashi</surname><given-names>K.</given-names></name>
<name><surname>Harano</surname><given-names>K.</given-names></name>
<name><surname>Mizutani</surname><given-names>M.</given-names></name>
<name><surname>Tanioka</surname><given-names>M.</given-names></name>
<name><surname>Takahashi</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Phase 1 study of the liposomal formulation of eribulin (e7389-lf): Results from the breast cancer expansion cohort</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>168</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.03.004</pub-id><pub-id pub-id-type="pmid">35500404</pub-id>
</element-citation></ref><ref id="B141-pharmaceutics-17-00276"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawazoe</surname><given-names>A.</given-names></name>
<name><surname>Yamamoto</surname><given-names>N.</given-names></name>
<name><surname>Sugimoto</surname><given-names>N.</given-names></name>
<name><surname>Kawakami</surname><given-names>H.</given-names></name>
<name><surname>Oshima</surname><given-names>T.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>K.</given-names></name>
<name><surname>Hino</surname><given-names>K.</given-names></name>
<name><surname>Hirao</surname><given-names>M.</given-names></name>
<name><surname>Kurokawa</surname><given-names>Y.</given-names></name>
<name><surname>Kawakami</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Phase ii study of the liposomal formulation of eribulin (e7389-lf) in combination with nivolumab: Results from the gastric cancer cohort</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2024</year><volume>30</volume><fpage>1264</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1768</pub-id><pub-id pub-id-type="pmid">38295160</pub-id>
</element-citation></ref><ref id="B142-pharmaceutics-17-00276"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papayannidis</surname><given-names>C.</given-names></name>
<name><surname>Wadolowska</surname><given-names>C.</given-names></name>
<name><surname>Sica</surname><given-names>S.</given-names></name>
<name><surname>Machlinski</surname><given-names>B.</given-names></name>
<name><surname>Lech-Maranda</surname><given-names>E.</given-names></name>
<name><surname>Abbate</surname><given-names>C.</given-names></name>
<name><surname>Wasyl</surname><given-names>E.</given-names></name>
<name><surname>Waymack</surname><given-names>P.</given-names></name>
<name><surname>Priebe</surname><given-names>W.</given-names></name>
<name><surname>Dempke</surname><given-names>W.</given-names></name>
</person-group><article-title>Preliminary results from a phase 1/2 study of liposomal annamycin (l-ann) in combination with cytarabin for the treatment of patients with acute myeloid leukemia (aml) that is refractory to or relapsed (r/r) after induction therapy</article-title><source>Blood</source><year>2023</year><volume>142</volume><issue>(Suppl. S1)</issue><fpage>5948</fpage><pub-id pub-id-type="doi">10.1182/blood-2023-184493</pub-id></element-citation></ref><ref id="B143-pharmaceutics-17-00276"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumagai</surname><given-names>Y.</given-names></name>
<name><surname>Inagaki</surname><given-names>R.</given-names></name>
<name><surname>Shimizu</surname><given-names>K.</given-names></name>
<name><surname>Hirose</surname><given-names>W.</given-names></name>
<name><surname>Shimada</surname><given-names>N.</given-names></name>
<name><surname>Hayashi</surname><given-names>K.</given-names></name>
<name><surname>Fukuoka</surname><given-names>Y.</given-names></name>
<name><surname>Matsuoka</surname><given-names>M.</given-names></name>
<name><surname>Kamioka</surname><given-names>S.</given-names></name>
<name><surname>Ban</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Abstract 5724: Preclinical evaluation of a novel chk1 inhibitor encapsulated within the liposome, smp-3124, for the treatment of solid cancer</article-title><source>Cancer Res.</source><year>2024</year><volume>84</volume><fpage>5724</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2024-5724</pub-id></element-citation></ref><ref id="B144-pharmaceutics-17-00276"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diringer</surname><given-names>M.-C.</given-names></name>
<name><surname>Coliat</surname><given-names>P.</given-names></name>
<name><surname>Mathieu</surname><given-names>C.</given-names></name>
<name><surname>Laurent</surname><given-names>N.</given-names></name>
<name><surname>Mura</surname><given-names>C.</given-names></name>
<name><surname>Banerjee</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Grabowska</surname><given-names>A.</given-names></name>
<name><surname>Ritchie</surname><given-names>A.</given-names></name>
<name><surname>Clarke</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Clinically translatable transcrocetin delivery platform for correction of tumor hypoxia and enhancement of radiation therapy effects</article-title><source>Small</source><year>2023</year><volume>19</volume><fpage>2205961</fpage><pub-id pub-id-type="doi">10.1002/smll.202205961</pub-id></element-citation></ref><ref id="B145-pharmaceutics-17-00276"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gagliardi</surname><given-names>M.</given-names></name>
<name><surname>Ashizawa</surname><given-names>A.</given-names></name>
</person-group><article-title>The combination of liposomal bcl-2 antisense oligonucleotide (bp1002) with decitabine is efficacious in venetoclax-resistant cells</article-title><source>Cancer Res.</source><year>2021</year><volume>81</volume><fpage>939</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2021-939</pub-id></element-citation></ref><ref id="B146-pharmaceutics-17-00276"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gabizon</surname><given-names>A.</given-names></name>
<name><surname>Shmeeda</surname><given-names>H.</given-names></name>
<name><surname>Tahover</surname><given-names>E.</given-names></name>
<name><surname>Kornev</surname><given-names>G.</given-names></name>
<name><surname>Patil</surname><given-names>Y.</given-names></name>
<name><surname>Amitay</surname><given-names>Y.</given-names></name>
<name><surname>Ohana</surname><given-names>P.</given-names></name>
<name><surname>Sapir</surname><given-names>E.</given-names></name>
<name><surname>Zalipsky</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of promitil&#x000ae;, a lipidic prodrug of mitomycin c in pegylated liposomes: From bench to bedside</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#x02013;155</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.027</pub-id></element-citation></ref><ref id="B147-pharmaceutics-17-00276"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rizvi</surname><given-names>I.</given-names></name>
<name><surname>Nath</surname><given-names>S.</given-names></name>
<name><surname>Obaid</surname><given-names>G.</given-names></name>
<name><surname>Ruhi</surname><given-names>M.K.</given-names></name>
<name><surname>Moore</surname><given-names>K.</given-names></name>
<name><surname>Bano</surname><given-names>S.</given-names></name>
<name><surname>Kessel</surname><given-names>D.</given-names></name>
<name><surname>Hasan</surname><given-names>T.</given-names></name>
</person-group><article-title>A combination of visudyne and a lipid-anchored liposomal formulation of benzoporphyrin derivative enhances photodynamic therapy efficacy in a 3d model for ovarian cancer</article-title><source>Photochem. Photobiol.</source><year>2019</year><volume>95</volume><fpage>419</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1111/php.13066</pub-id><pub-id pub-id-type="pmid">30499113</pub-id>
</element-citation></ref><ref id="B148-pharmaceutics-17-00276"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolger</surname><given-names>G.T.</given-names></name>
<name><surname>Licollari</surname><given-names>A.</given-names></name>
<name><surname>Tan</surname><given-names>A.</given-names></name>
<name><surname>Greil</surname><given-names>R.</given-names></name>
<name><surname>Vcelar</surname><given-names>B.</given-names></name>
<name><surname>Greil-Ressler</surname><given-names>S.</given-names></name>
<name><surname>Weiss</surname><given-names>L.</given-names></name>
<name><surname>Sch&#x000f6;nlieb</surname><given-names>C.</given-names></name>
<name><surname>Magnes</surname><given-names>T.</given-names></name>
<name><surname>Radl</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Pharmacokinetics of liposomal curcumin (lipocurc&#x02122;) infusion: Effect of co-medication in cancer patients and comparison with healthy individuals</article-title><source>Cancer Chemother. Pharmacol.</source><year>2019</year><volume>83</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1007/s00280-018-3730-5</pub-id><pub-id pub-id-type="pmid">30430227</pub-id>
</element-citation></ref><ref id="B149-pharmaceutics-17-00276"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kloesch</surname><given-names>B.</given-names></name>
<name><surname>Gober</surname><given-names>L.</given-names></name>
<name><surname>Loebsch</surname><given-names>S.</given-names></name>
<name><surname>Vcelar</surname><given-names>B.</given-names></name>
<name><surname>Helson</surname><given-names>L.</given-names></name>
<name><surname>Steiner</surname><given-names>G.</given-names></name>
</person-group><article-title>In vitro study of a liposomal curcumin formulation (lipocurc&#x02122;): Toxicity and biological activity in synovial fibroblasts and macrophages</article-title><source>In Vivo</source><year>2016</year><volume>30</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">27381602</pub-id>
</element-citation></ref><ref id="B150-pharmaceutics-17-00276"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Routman</surname><given-names>D.M.</given-names></name>
<name><surname>Van Abel</surname><given-names>K.</given-names></name>
<name><surname>Bartemes</surname><given-names>K.</given-names></name>
<name><surname>Foster</surname><given-names>N.R.</given-names></name>
<name><surname>Riebel</surname><given-names>N.</given-names></name>
<name><surname>Wood</surname><given-names>L.</given-names></name>
<name><surname>Nagelschneider</surname><given-names>A.A.</given-names></name>
<name><surname>Garcia</surname><given-names>J.J.</given-names></name>
<name><surname>Chintakuntlawar</surname><given-names>A.V.</given-names></name>
<name><surname>Price</surname><given-names>K.</given-names></name>
</person-group><article-title>A vaccine (pds0101) alone or in combination with pembrolizumab for the treatment of locally advanced human papillomavirus-associated oropharynx cancer</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2024</year><volume>118</volume><fpage>e21</fpage><lpage>e22</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2024.01.051</pub-id></element-citation></ref><ref id="B151-pharmaceutics-17-00276"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1372</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27041372</pub-id><pub-id pub-id-type="pmid">35209162</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00276-f001"><label>Figure 1</label><caption><p>The tumor targeting of the MRI contrast agent Magnevist by LNC-NS-629 in a mouse breast cancer model. Adapted with permission from Mikhaylov et al. (2014) [<xref rid="B33-pharmaceutics-17-00276" ref-type="bibr">33</xref>].</p></caption><graphic xlink:href="pharmaceutics-17-00276-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00276-f002"><label>Figure 2</label><caption><p>Different liposome types differing in their lipid composition or surface modifications.</p></caption><graphic xlink:href="pharmaceutics-17-00276-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00276-f003"><label>Figure 3</label><caption><p>A schematic diagram of liposome preparation. Lipid components dissolved in an organic solvent are dried to form thin lipid films, which are then hydrated with an aqueous solution to produce multilamellar vesicles. (<bold>a</bold>) Extrusion through a polycarbonate membrane to form unilamellar vesicles with a uniform size. (<bold>b</bold>) Sonication using a water bath to break down multilamellar vesicles into smaller unilamellar vesicles.</p></caption><graphic xlink:href="pharmaceutics-17-00276-g003" position="float"/></fig></floats-group></article>